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ORIGINAL RESEARCH
Associations of Observational and 
Genetically Determined Caffeine Intake 
With Coronary Artery Disease and Diabetes 
Mellitus
M. Abdullah Said , MD; Yordi J. van de Vegte, BSc; Niek Verweij, PhD; Pim van der Harst, MD, PhD
BACKGROUND: Caffeine is the most widely consumed psychostimulant and is associated with lower risk of coronary artery 
disease (CAD) and type 2 diabetes mellitus (T2DM). However, whether these associations are causal remains unknown. This 
study aimed to identify genetic variants associated with caffeine intake, and to investigate evidence for causal links with CAD 
or T2DM. In addition, we aimed to replicate previous observational findings.
METHODS AND RESULTS: Observational associations were tested within UK Biobank using Cox regression analyses. Moderate 
observational caffeine intakes from coffee or tea were associated with lower risks of CAD or T2DM, with the lowest risks at 
intakes of 121 to 180 mg/day from coffee for CAD (hazard ratio [HR], 0.77 [95% CI, 0.73–0.82; P<1×10−16]), and 301 to 360 mg/
day for T2DM (HR, 0.76 [95% CI, 0.67–0.86]; P=1.57×10−5). Next, genome-wide association studies were performed on self-
reported caffeine intake from coffee, tea, or both in 407 072 UK Biobank participants. These analyses identified 51 novel 
genetic variants associated with caffeine intake at P<1.67×10−8. These loci were enriched for central nervous system genes. 
However, in contrast to the observational analyses, 2-sample Mendelian randomization analyses using the identified loci in 
independent disease-specific cohorts yielded no evidence for causal links between genetically determined caffeine intake and 
the development of CAD or T2DM.
CONCLUSIONS: Mendelian randomization analyses indicate genetically determined higher caffeine intake might not protect 
against CAD or T2DM, despite protective associations in observational analyses.
Key Words: caffeine intake ■ coronary artery disease ■ genetics ■ Mendelian randomization ■ type 2 diabetes mellitus
Caffeine is the most commonly consumed psycho-stimulant in the world and is readily available in coffee, tea, and other food products.1 Previous 
observational studies and meta-analyses have gen-
erally reported beneficial associations between mod-
erate intake of coffee, the main dietary source of 
caffeine,1 and risk of cardiovascular disease2 and type 
2 diabetes mellitus (T2DM),3 as well as cardiovascu-
lar and all-cause mortality.4,5 Contrasting results have 
been reported as well for cardiovascular disease out-
comes, including coronary artery disease (CAD),2,6–9 
and therefore coffee and tea are not generally included 
in dietary guidelines.10 Given its widespread consump-
tion, altering caffeine intake might be an interesting 
way to influence population-wide risk of developing 
CAD and T2DM.
Because of the observational design of previous 
studies, which include many cross-sectional and 
case-control studies, it is difficult to provide insight into 
causal relationships. Genome-wide association studies 
(GWASs) have identified several single-nucleotide poly-
morphisms (SNPs) associated with caffeine or coffee 
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intake through genes such as AHR and CYP1A2, which 
affect the metabolism of caffeine.11–17 Unlike traditional 
observational studies, Mendelian randomization (MR) 
analyses have the advantageous applicability of un-
covering causal links using genetic variants, which are 
randomly allocated at conception, as instrumental vari-
ables for modifiable risk factors to test potential causal 
links with disease outcomes. So far, MR analyses be-
tween genetically determined higher caffeine intake 
and risk of CAD7,18 or T2DM19 failed to provide support 
for a causal link. However, these studies used only few 
SNPs and investigated coffee as the sole source of 
caffeine.
Here, we investigated the observational asso-
ciations between habitual caffeine intake from cof-
fee, tea, or both with new-onset CAD and T2DM in 
a large prospective observational cohort. To further 
our knowledge of the genetic architecture underlying 
caffeine intake, we carried out GWASs for caffeine 
intake from coffee, tea, or both in over 400 000 par-
ticipants from the UK Biobank to identify novel vari-
ants for caffeine intake. Using this set of SNPs, we 
aimed to investigate the causal relationship between 
caffeine intake with CAD and T2DM in large indepen-
dent cohorts.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request. GWAS summary statistics generated 
during the present study will be made available in the 
following repository: https://doi.org/10.17632/ d8nwk 
m7p9p.1.
Study Population
The UK Biobank study is a population-based pro-
spective cohort whose design and population have 
been described previously.20 From 2006 to 2010, 
>500  000 individuals between the ages of 40 and 
69  years were recruited in the United Kingdom. All 
participants gave informed consent,21 and the UK 
Biobank study was approved by the North West 
Multi-centre Research Ethics committee.22 Details 
regarding the UK Biobank study population are pro-
vided in Data S1.
Ascertainment of Coffee and Tea Intake
During the first visit to the assessment center, daily 
coffee and tea intake were assessed by asking par-
ticipants, “How many cups of coffee do you drink 
each day? (Include decaffeinated coffee)” and “How 
many cups of tea do you drink each day? (Include 
black and green tea).” In addition, coffee drinkers 
were asked what type of coffee they usually drink. 
Caffeine intake was calculated as the number of 
cups of coffee or tea multiplied by the caffeine con-
tent per cup.23 Combined caffeine intake from both 
coffee and tea was calculated as the sum of the daily 
caffeine intake from coffee and tea from individuals 
who provided data on both. Full details on the ascer-
tainment of coffee, tea, and daily caffeine intake are 
provided in Data S1.
CAD and T2DM Prevalence and Incidence 
in the UK Biobank
Prevalence at baseline and incidence of new-onset 
CAD and T2DM cases within UK Biobank were, 
per prior analysis,24 based on self-reported data, 
International Classification of Diseases, Ninth Revision 
CLINICAL PERSPECTIVE
What Is New?
• Leveraging data from >400 000 individuals, we 
identified 51 novel genetic loci associated with 
caffeine intake.
• We confirmed phenotypic associations be-
tween caffeine intake and the development 
of coronary artery disease or type 2 diabetes 
mellitus, but by exploiting instrumental variable 
analyses we found no evidence for causality of 
this association.
What Are the Clinical Implications?
• Our data do not support recommending caf-
feine intake to protect against the development 
of coronary artery disease of type 2 diabetes 
mellitus.
Nonstandard Abbreviations and Acronyms
CARDIoGRAMplusC4D  Coronary Artery 
Disease Genome wide 
Replication and 
Meta-analysis plus The 
Coronary Artery 
Disease Genetics
DIAGRAM   Diabetes Genetics 
Replication And 
Meta-analysis
eQTL   expression quantitative 
trait locus
MR   Mendelian 
randomization
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(ICD-9) and Tenth Revision (ICD-10)25 coded primary 
and secondary diagnoses, operation codes,26 and 
death attributable to either condition from inclusion 
in the UK Biobank until end of follow-up (March 31, 
2017, for participants from England; February 29, 
2016, for Wales; and October 31, 2016, for Scotland) 
as described in Data S1. Incident cases that were 
based on self-reported diagnoses during follow-up 
visits were included only if there were no events re-
corded according to the ICD-9 or ICD-10 or opera-
tion codes data and only if the participant did not 
report this in the previous visit. If the participant was 
the same age as the reported age of diagnosis, the 
median date between the visit and the participant’s 
birthday was taken as date of event. If the age of di-
agnosis was before the participant’s current age, we 
took the median date of the year of the reported age 
of diagnosis counted from the participant’s birthday. 
If age of diagnosis was not available, we took the me-
dian date between the visit of the first self-reported 
diagnosis and the previous visit. Individuals with a 
history of CAD or T2DM at inclusion were excluded 
from the respective observational analyses.
Covariates
At the first visit, weight (in kilograms) and height (in 
centimeters) were measured and used to calculate 
the body mass index (in kilograms per square meter). 
Age was calculated as the difference between date 
of birth and date of inclusion in the UK Biobank. Sex, 
ethnicity, weekly alcohol intake (UK units) and ac-
tive smoking at inclusion were self-reported. Weekly 
alcohol intake was right-skewed and therefore log2 
transformed for participants who provided this data. 
For participants without these accurate data on the 
number of units, we estimated the weekly alcohol 
intake using a more crude questionnaire of alcohol 
intake frequency where participants were asked, 
“About how often do you drink alcohol?” For this, 
we fitted a linear regression between with the log2-
transformed weekly alcohol intake and alcohol intake 
frequency in participants with both measures, and 
predicted weekly alcohol intake on the remaining in-
dividuals. The Townsend Deprivation Index, a proxy 
for socioeconomic status, was provided by the UK 
Biobank and inverse rank normalized because of a 
right-skewed distribution.24
Genotyping and Imputation in UK Biobank
UK Biobank participants were genotyped using cus-
tom Affymetrix Axiom (UK Biobank Lung Exome Variant 
Evaluation27 or UK Biobank) arrays. The genotyping 
methods, arrays, and quality-control procedures have 
been described previously in detail28,29 and are briefly 
described in Data S1.
Statistical Analysis
We performed multivariable Cox regression analyses 
to test the association of observational caffeine intake 
per 60 mg caffeine (equivalent to the caffeine content 
of 1 cup of instant coffee or 2 cups of tea) with new-
onset CAD and T2DM in the UK Biobank. Hazard ra-
tios with 95% CIs were calculated for 1 to 60, 61 to 
120, 121 to 180, 181 to 240, 241 to 300, 301 to 360, 
or >360 mg of caffeine from coffee or combined, com-
pared with individuals who drank 0 mg. Because of the 
lower caffeine content per cup of tea compared with 
caffeinated coffee, the hazard ratios and 95% CIs for 
caffeine from tea were calculated for 1 to 60, 61 to 120, 
121 to 180, or >180 mg (equivalent to >6 cups of tea) 
of caffeine compared with individuals who had 0-mg 
intake from tea. The time scale for the Cox regression 
analyses was from inclusion in the UK Biobank until 
the outcome of interest, death or end of follow-up. Cox 
regression analyses were performed unadjusted and 
adjusted for age, sex, body mass index, active smok-
ing, Townsend Deprivation Index, and weekly alco-
hol intake using Stata version 15 (StataCorp, College 
Station, TX).
All genetic analyses were adjusted for age, sex, 
genotyping array, and the first 30 genetic principal 
components to adjust for population stratification. 
We performed separate GWASs for inverse rank 
normalized combined caffeine intake, caffeine from 
coffee, and caffeine from tea in 19  400  838 SNPs 
using BOLT-LMM version 2.3.1 software (Broad 
Institute, Cambridge, MA).30 A Bonferroni corrected 
P<1.67×10−8 (traditional GWAS significance thresh-
old of 5×10−8/3) was considered genome-wide sig-
nificant. This significance threshold is conservative, 
considering that our phenotypes are correlated 
with Spearman’s rank correlation coefficients be-
tween phenotype pairs ranging from r=−0.33 to 0.71 
(Table S1). Details of the GWAS analyses, functional 
annotation of candidate genes,31–35 and biological 
pathways are provided in Data S1.
We performed MR analyses using previ-
ously published summary statistics from the 
CARDIoGRAMplusC4D (Coronary Artery Disease 
Genome wide Replication and Meta-analysis plus 
The Coronary Artery Disease Genetics) consortium 
(123 504 controls and 60 801 [33.0%] cases)36 and 
the DIAGRAM Diabetes Genetics Replication And 
Meta-analysis)) consortium (132  532 controls and 
26  676 [16.8%] cases)37 to gain insight into poten-
tial causal relationships between caffeine intake 
and CAD or T2DM, respectively. Lead SNPs of 
each caffeine intake trait that reached P<1.67×10−8 
were used to create a weighted genetic risk score 
and were also used as instrumental variables in the 
MR. Each genetic risk score was created using an 
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effect alleles (0, 1, or 2) per individual after multiply-
ing it with the effect size between the SNP and the 
GWAS phenotype. Statistical power for the MR with 
a binary outcome was calculated using an alpha of 
0.05 and the explained variance of each genetic risk 
score, as described previously.38 For the MR, SNPs 
that were not available in CARDIoGRAMplusC4D or 
DIAGRAM were replaced with proxies with R2>0.8, 
and were otherwise excluded from the MR analyses 
if no eligible proxies were available. SNP effects were 
harmonized across studies using the built-in feature 
of the TwoSampleMR package in R (R Foundation 
for Statistical Computing, Vienna, Austria). The asso-
ciation between genetically determined higher caf-
feine intake and CAD or T2DM was assessed using 
fixed-effects inverse-variance weighted meta-analy-
ses. Odds ratios (ORs) with 95% CIs are presented 
for the MR outcomes. To maximize the likelihood of 
reporting true findings, α was set at 0.005 instead 
of 0.05.39 Associations with P<0.05 were considered 
suggestively significant. We assessed potential weak 
instrument bias per SNP using the F-statistic40 and 
I2GX.
41 We determined the I2 index.42 Cochran’s Q, 
Rücker’s Q′, and Q-Q′43 to test for heterogeneity and 
thus potential pleiotropy. MR-Egger,43 MR Pleiotropy 
Residual Sum and Outlier44 and MR inverse-variance 
weighted random effects43 were used as pleiotropy 
analyses. MR-Steiger filtering45 was performed to 
remove variants more strongly associated with the 
outcome than the exposure. Weighted median and 
weighted mode-based estimator MR analyses46 were 
performed as additional sensitivity analyses. Details 
of the MR analyses are provided in Data S1.
RESULTS
Cohort Characteristics
Of 502 525 UK Biobank individuals, 362 316 were 
available for the combined caffeine intake analy-
ses, 373 522 for caffeine from coffee, and 395 866 
for caffeine from tea (Figure  S1). Baseline char-
acteristics are shown in Table, per caffeine intake 
trait in Table S2, and stratified by caffeine intake in 
Tables  S3 through S5. Median (interquartile range) 
combined caffeine intake was 205 (120–290) mg/
day, from coffee 85 (3–180) mg/day, and from tea 90 
(60–150) mg/day.
Associations of Observational Caffeine 
Intake With CAD and T2DM
During nearly 10  years (median, 8.1  years; inter-
quartile range, 7.5–8.6) of follow-up in 345  809 
participants without history of CAD and 347 718 par-
ticipants without history of T2DM, 14 681 (4.2%) indi-
viduals developed CAD, and 6982 (2.0%) developed 
T2DM in the combined caffeine cohort. Results for 
unadjusted analyses are presented in Tables S6 and 
S7. In multivariable adjusted analyses (Tables S8 and 
S9), combined caffeine intake was very modestly 
or not associated with CAD or T2DM. However, the 
individual components, caffeine from coffee or tea, 
did show associations with lower risks of new-onset 
CAD and T2DM (Figure  1A and 1B, respectively). 
Overall, the associations between caffeine from cof-
fee or tea with CAD and T2DM followed U-curve–
type shapes, with the highest protective effects of 
caffeine intake from coffee on CAD at moderate in-
takes (121–180 mg/day), compared with no, lower, or 
higher intakes. Associations between caffeine from 
coffee with CAD or T2DM were not appreciably dif-
ferent when additionally adjusted for caffeine from 
tea, nor were the associations for caffeine from tea 
when additionally adjusted for caffeine from coffee 
(Table S10). Overall, caffeine intake from coffee was 
associated with lower risks of CAD and T2DM com-
pared with caffeine from tea or combined. To deter-
mine whether this may be attributable to confounding 
by other, noncaffeine, substances, we stratified the 
Table 1. Baseline Characteristics of All Included 407 072 
UK Biobank Participants
Characteristics Men Women
Total, N 186 968 220 104
Age, y, mean (SD) 57.16 (8.08) 56.72 (7.92)
Daily caffeine intake, mg/d, median (IQR)
Combined caffeine 210 (150–300) 180 (120–270)
Caffeine from coffee 85 (6–180) 60 (3–170)
Caffeine from tea 90 (60–150) 90 (60–150)
Blood pressure, mm Hg, mean (SD)
Systolic 139.60 (16.15) 128.74 (17.88)
Diastolic 84.69 (8.22) 79.94 (8.20)
Active smoker, N (%)
No 164 791 (88.1) 200 946 (91.3)
Yes 22 177 (11.9) 19 158 (8.7)
Body mass index , kg/m2, 
mean (SD)
27.85 (4.23) 27.05 (5.13)
Weekly alcohol intake, UK 
units, median (IQR)
15.40 (5.50, 28.40) 6.40 (1.60, 13.20)
Hypertension, N (%)
No 119 965 (64.2) 160 881 (73.1)
Yes 67 003 (35.8) 59 223 (26.9)
Hyperlipidemia, N (%)
No 139 471 (74.6) 188 444 (85.6)
Yes 47 497 (25.4) 31 660 (14.4)
Combined caffeine intake was calculated as the sum of caffeine 
intake from coffee and tea. Body mass index was calculated as weight 
in kilograms divided by height in meters squared. Smoking status and 





 http://ahajournals.org by on D
ecem
ber 10, 2020
J Am Heart Assoc. 2020;9:e016808. DOI: 10.1161/JAHA.120.016808 5
Said et al Caffeine Intake, Coronary Artery Disease and Diabetes
analyses by cups of decaffeinated or caffeinated 
coffee and found similar results. Both caffeinated 
and decaffeinated coffee were associated with lower 
risk of CAD and T2DM compared with no or high (>6 
cups for caffeinated coffee; >3 for decaffeinated cof-
fee) intake (Table S11).
GWAS on Caffeine Intake Traits
We identified 62 SNPs in 37 loci: 32 novel, associated 
with combined caffeine intake (Figure 2; Table S12); 
27 SNPs in 24 loci (20 novel) with caffeine from cof-
fee (Figure S2; Table S13); and 27 SNPs in 24 loci (21 
novel) with caffeine from tea (Figure S3; Table S14). 
Figure 1. Associations between observational caffeine intake with new-onset coronary artery disease (A) and type 2 
diabetes mellitus (B).
Hazard ratios (HR) with 95% CIs were calculated using Cox regression analyses, adjusted for age, sex, active smoking, body mass 
index, and log-transformed weekly alcohol intake. Estimates <1 indicate a beneficial association between caffeine intake and outcome. 
Sixty milligrams of caffeine is equivalent to 1 cup of instant coffee or 2 cups of tea.
Intake (mg/day) Ntotal (Ncases )IC%59(RH) P value
0.50 1.0 1.5 2.0
Hazard ratio (95% CI)
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Figure 2. Manhattan plot for combined caffeine intake.
Manhattan plot showing the results for the genome-wide associations with combined caffeine intake in the UK Biobank with the −
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When combined on the basis of the lowest P value 
over all traits, 73 unique SNPs in 5 known and 51 
novel loci were associated with ≥1 caffeine trait 
(Figure  S4, Table  S15). In total, 15 of 20 previously 
reported SNPs were replicated within 1  MB of our 
sentinel SNPs (Table S16). Regional association plots 
for each independent locus per trait are presented in 
Figures S5 through S7 and QQ plots in Figures S8 
through S10. The sentinel SNPs identified in the 
combined caffeine, caffeine from coffee, and caffeine 
from tea GWAS explained 1.32%, 0.59%, and 0.45% 
of variance in caffeine intake of their respective trait. 
The heritability rate (h2
g
) for all SNPs in the GWAS was 
8.2% for combined caffeine intake, 6.1% for caffeine 
from coffee, and 7.1% for caffeine from tea.
Using the genetic risk score of each GWAS, each 
unit change in genetically determined caffeine intake 
was consistent with 131.6  mg combined caffeine 
intake, 134.5  mg caffeine intake from coffee, and 
86.1 mg caffeine intake from tea. In coffee drinkers, 
depending on the type of coffee usually drunk, each 
unit related from 1.5 cup of decaffeinated coffee to 
2.1 cups of instant coffee (Table S17).
Candidate Genes and Deeper Insights 
Into Biology
We explored the potential biology of the sentinel SNPs 
per GWAS by prioritizing potentially causal genes in 
these loci based on proximity, expression quantita-
tive trait locus (eQTL) analyses, and data-driven ex-
pression-prioritized integration for complex traits. In 
total, we identified 48 candidate genes for combined 
caffeine intake, 27 for caffeine from coffee, and 40 
for caffeine from tea (Figure 3). We identified the pre-
viously reported AHR, CYP1A1, and POR genes in all 
3 GWASs. In addition, 2 novel genes, GOLPH3L and 
HORMAD1, were associated with all caffeine traits.
Across 209 tissue and cell types, central nervous sys-
tem tissues were most enriched for SNPs associated 
Figure 3. Venn diagram of candidate genes associated with caffeine intake.
Candidate genes were prioritized based on proximity, data-driven expression-prioritized integration for 
complex traits, and expression quantitative trait locus mapping for combined caffeine intake, caffeine 
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with caffeine from tea and combined, but none with 
caffeine from coffee (Table S18). Furthermore, 6 com-
bined caffeine intake loci, and 3 loci each of caffeine 
from coffee or tea, contained variants with eQTLs in at 
least 1 tissue. The strongest associations were found 
for rs768283768 near HORMAD1 and GOLPH3L, 
which tagged multiple tissues (Table S19).
Genetically Determined Caffeine Intake 
and CAD
The association between genetically determined caf-
feine intake and CAD was tested in the independent 
CARDIoGRAMplusC4D cohort (123 504 controls and 
60 801 [33.0%] cases). In total, 35 SNPs from caffeine 
for combined caffeine intake, 22 for caffeine from cof-
fee (rs2298527 excluded based on intermediate allele 
frequency in CARDIoGRAMplusC4D), and 24 for caf-
feine from tea (Table S20 through S22). F-statistics indi-
cated low chances of weak instrument bias (Table S23) 
and I2GX indicated low chances of measurement error 
in MR-Egger (Table S24). However, I2 and Cochran’s Q 
indicated heterogeneity, and thus potential pleiotropy, 
for all caffeine traits (Table S24). Using the random ef-
fects inverse-variance weighted method as indicated 
by the nonsignificant Q-Q′ and MR-Egger intercepts, 
we found that genetically determined caffeine intake 
from combined or coffee were not associated with 
CAD (OR, 1.12 [95% CI, 0.80–1.40], P=0.31; OR 1.26 
[95% CI, 0.82–1.93], P=0.28, respectively). MR-Egger 
was used for caffeine from tea because the Q-Q′ was 
significant; however, also for caffeine from tea, no 
association with CAD was indicated (OR, 1.60 [95% 
CI, 0.75–3.44], P=0.24). MR Pleiotropy Residual Sum 
and Outlier analyses corroborated these findings 
for all traits, with and without trimming outlier SNPs 
(Table  S25). MR-Steiger filtering also did not attenu-
ate the results for any caffeine trait (Table S26). Finally, 
weighted median and mode-based analyses also indi-
cated no association between genetically determined 
caffeine intake and CAD. Individual SNP effects are 
shown in Figures S11 through S13 and the MR analy-
ses in Figure 4A.
Genetically Determined Caffeine Intake 
and T2DM
The association between genetically determined 
caffeine intake and T2DM was investigated in the 
DIAGRAM cohort (132 532 controls and 26 676 [16.8%] 
cases). In DIAGRAM, 35 SNPs for combined caffeine 
intake, 23 SNPs for caffeine from coffee, and 24 SNPs 
for caffeine from tea were used (Tables S27 through 
S29). Also here, I2 indices and Cochran’s Q indicated 
pleiotropy for all traits, and the MR-Egger intercept 
was not significant. However, because the Q-Q′ was 
Figure 4. Mendelian randomization results for genetically determined higher caffeine intake (per SD) on coronary artery 
disease (A) and type 2 diabetes mellitus (B).
Odds ratios (OR) with 95% CIs are provided per standard deviation increase in genetically determined caffeine intake from combined, 
coffee, or tea. Number of single-nucleotide polymorphisms (SNPs) included are shown per method. Estimates <1.0 indicate a 
beneficial association between genetically determined caffeine intake and outcome. MR-PRESSO indicates Mendelian Randomization 
Pleiotropy Residual Sum and Outlier.
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significant for all traits, we focused on the MR-Egger 
estimate for the causal effect. The MR-Egger analyses 
indicated no association between genetically deter-
mined higher caffeine intake from any trait with risk of 
T2DM (OR, 1.06 [95% CI, 0.67–1.68], P=0.79 for com-
bined caffeine intake; OR, 1.07 [95% CI, 0.33–3.54], 
P=0.91 for caffeine from coffee; OR, 2.36 [95% CI, 
0.62–8.91], P=0.22 for caffeine from tea; Figure  4B; 
estimates per SNP in Figures  S14 through S16). 
Additional analyses using MR Pleiotropy Residual Sum 
and Outlier and MR-Steiger also found no associations 
between caffeine intake with T2DM after respectively 
trimming outliers and filtering (Tables  S25 and S26). 
Finally, also weighted and mode-based estimator MR 
analyses were in line with these findings and indicated 
no association with T2DM.
Combined Caffeine Intake–Specific 
Variants
In total, 18 variants were associated with combined 
caffeine intake, of which the annotated genes do not 
overlap with those of caffeine from coffee or caffeine 
from tea. However, these variants were most strongly 
associated with combined caffeine intake compared 
with caffeine from tea or coffee and had concord-
ant betas across all traits (Table S15). This suggests 
that these variants act on both caffeine from coffee 
and caffeine from tea. We repeated the MR analy-
ses using these variants or their proxies available in 
CARDIoGRAMplusC4D and DIAGRAM. Similar to the 
MR using all combined caffeine intake variants, we 
found no associations with CAD or T2DM.
Moderate Versus Extreme Caffeine 
Intakes From Coffee or Tea
Because of the U-shaped curve observed in the ob-
servational analyses between caffeine from coffee and 
caffeine from tea with CAD or T2DM, we performed 
exploratory analyses to investigate variants associated 
with moderate caffeine intake from coffee or tea sepa-
rately. Extremes of caffeine intake (0 and >360  mg/
day for coffee and 0 and >120 mg/day for tea) were 
taken together and values between the extremes as 
moderate intake. A total of 373 522 individuals (99 427 
[26.6%] with moderate intake) were included in the 
GWAS for moderate caffeine consumption from cof-
fee, and 395 866 (188 013 [47.8%] with moderate in-
take) in the GWAS for moderate caffeine consumption 
from tea. However, GWAS on either phenotype found 
no variants at P<1.67×10−8 or P<5×10−8.
DISCUSSION
In this large prospective study, we observed U-type 
associations between observational caffeine intake 
with CAD and T2DM, although similar intakes from dif-
ferent sources had dissimilar effect sizes. In addition, 
we identified 51 novel genetic loci associated with caf-
feine intake, more than tripling the number of known 
loci.11–17 In contrast to the observational analyses, ge-
netic causal inference analyses indicated that geneti-
cally determined caffeine intake was not associated 
with CAD or T2DM.
Our observational findings are concordant with 
previous studies showing inverse or U-type asso-
ciations between caffeine intake with CAD2,47 and 
T2DM.3,47,48 A meta-analysis in 1 283 685 individuals 
(28 347 CAD cases) estimated a relative risk of 0.89 
(95% CI, 0.85–0.94) for CAD at 3 to 5 cups of coffee 
daily and a neutral effect at higher intakes (>360 mg 
or >6 cups of coffee) compared with no intake.2 A 
plausible explanation for the U-type shape of the as-
sociation is that coffee is a liquid extract of coffee 
beans and it contains a complex chemical mixture 
of biologically active compounds, some with ben-
eficial and others with harmful effects.49 At moder-
ate intakes, the beneficial effects could outweigh or 
counteract the harmful effects, whereas at higher in-
takes the harmful effects may counterbalance this.2 
Our results for T2DM are in line with the most recent 
meta-analysis, which reported a relative risk of 0.70 
(95% CI, 0.65–0.75) in individuals who consumed 5 
cups of coffee per day compared with nondrinkers, 
although they reported no U-type associations.50 The 
hypothesis that moderate caffeine intake may have 
beneficial effects compared with extreme intakes 
is also not supported by our findings for combined 
caffeine intake. The null findings of the observational 
analyses for combined caffeine intake indicate that 
caffeine by itself is unlikely to affect disease risk. The 
current study used the largest number of caffeine 
SNPs to date from different dietary sources, which 
is relevant for this UK population, where tea is the 
second-largest source of caffeine1 and may con-
found the association. Using these SNPs in robust 
causal inference analyses, we found no associations 
between genetically determined higher or lower caf-
feine intake and CAD or T2DM. These findings are in 
line with previous MR studies of caffeine intake on 
CAD and T2DM.7,18,19 The null findings of the com-
bined caffeine intake SNPs can be considered a neg-
ative control for the observational findings. There is 
accumulating evidence that previous beneficial as-
sociations between caffeine intake with outcomes 
were attributable to residual confounding, most likely 
because of other compounds found in coffee3,7,18,19 
or smoking,51 since no difference in outcomes is re-
ported between decaffeinated and caffeinated cof-
fee for CAD8 or T2DM.3 Also, in the current study, 
we found that observational decaffeinated coffee 
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compared with caffeinated coffee. Caffeinated cof-
fee was more robustly associated with outcomes, 
but this is likely attributable to the larger number of 
caffeinated coffee drinkers. Furthermore, caffeine 
from coffee was generally associated with lower esti-
mates compared with caffeine from tea or combined, 
arguing against an independent effect of caffeine. In 
addition, both previous and the current MR analyses 
consistently lack evidence for causality, providing 
further argument against a protective effect of genet-
ically determined higher caffeine intake.
To our knowledge, this is the largest study to date 
to investigate the association of both observational 
and genetically determined caffeine intake from mul-
tiple sources with CAD and T2DM. This study also 
reports the largest number of caffeine intake–associ-
ated SNPs, while also replicating previously reported 
SNPs. These newly identified variants were then used 
in independent disease-specific cohorts for both CAD 
and T2DM in 2-sample MR analyses. The explained 
variance of the sentinel SNPs is comparable with pre-
viously published GWASs on coffee7,12 or alcohol52 in-
take, which range between 0.6% and 1.3%. However, 
the explained variance was of little influence on the sta-
tistical power for the MR.
This study has some limitations. In the current anal-
yses, caffeine intake was calculated on the basis of 
self-reported data at a single time point at baseline, 
which does not take into account possible changes in 
coffee- and tea-drinking habits. Furthermore, because 
the caffeine content of coffee may differ depending 
on the method of preparation,53,54 use of filter,55 and 
type of coffee bean,1 and individuals may drink sev-
eral types of coffee, the actual caffeine intake per 
day may differ from our calculation. We did not take 
into account caffeine intake from other sources such 
as cola or energy drinks, as this information was not 
available. In addition, the main MR analyses assume 
linear associations, whereas the causal associations 
might be nonlinear, with higher risks at low and high 
intakes, such as the U-shaped–curve associations ob-
served in the observational analyses. However, it was 
not possible to examine nonlinear associations in the 
MR analyses because these require individual-level 
data in the outcome cohorts, which were not available. 
The MR analyses should therefore be interpreted with 
caution at the extremes of caffeine intake. It remains 
unclear which genetic variants are responsible for the 
specific parts of the potential U-shaped–curve asso-
ciation, and we cannot exclude the possibility that the 
variants associated with caffeine intake from coffee or 
tea could have bidirectional effects on the association. 
Exploratory analyses to investigate the nonlinear asso-
ciation within the UK Biobank, however, indicate that 
there may be no genetic variants solely associated with 
moderate or extreme caffeine intake from coffee or tea.
Also, despite our sensitivity analyses to test for and 
minimize bias, especially from genetic pleiotropy in 
which the instrumental variables may act on the out-
come through other pathways than caffeine, this can-
not be completely excluded. We found evidence for 
heterogeneity in the MR for CAD and T2DM for all caf-
feine traits, indicating that pleiotropy cannot be ruled 
out. We therefore report the correct model per degree 
of pleiotropy as the main results and performed sev-
eral other sensitivity analyses to take this into account. 
Finally, the present analyses were performed in indi-
viduals of White British ancestry, which may limit the 
generalizability of the results to other populations.
In conclusion, this large prospective study showed 
inverse associations between observational caffeine 
intake with CAD and T2DM. However, effect sizes 
were similar between caffeinated and decaffeinated 
coffee; similar caffeine intakes from tea were as-
sociated with fewer inverse effects compared with 
caffeine from coffee. Furthermore, MR analyses in in-
dependent cohorts yielded no evidence for causality 
between genetically determined caffeine intake with 
CAD or T2DM. The main MR analysis results suggest 
that increasing caffeine intake may not be protective 
against the development of CAD or T2DM. However, 
these do not take into account the nonlinear associa-
tion observed within the observational analyses. We 
therefore encourage reanalysis of the results when 
more advanced methods to study nonlinear associ-
ations within a summary-based 2-sample MR setting 
emerge, without individual-level exposure data in the 
outcome cohort.
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UK Biobank participants 
The study design and population of the UK Biobank study have been described in detail previously20. Briefly, 
between 2006 and 2010 over 500,000 participants aged 40-69 years from the general population were recruited at 
22 assessment centers in the United Kingdom. Participants provided information on demographic, lifestyle, and 
other potentially health-related aspects through interviews, questionnaires, physical measurements as well as blood 
and urine samples20. All participants provided informed consent for the study at their first visit to the assessment 
center by agreeing to all individual statements of the consent form and providing their signature on an electronic 
pad21. The UK Biobank study has approval from the North West Multi-centre Research Ethics Committee for the 
UK, from the National information Governance Board for Health & Social Care for England and Wales, and from 
the Community health Index Advisory Group for Scotland22. 
 
Ascertainment of coffee and tea intake 
During the first visit to the assessment center, daily coffee and tea intake were assessed by asking participants 
“How many cups of coffee do you drink each day? (Include decaffeinated coffee)" and “How many cups of tea do 
you drink each day? (Include black and green tea)".  
Participants were asked to provide the average number of cups of either beverage they drink daily, based on their 
intake over the last year. We excluded participants who answered with “Less than one”, “Do not know” or “Prefer 
not to answer”. Participants who indicated to drink more than 10 cups of coffee or 20 cups of tea daily were asked 
to confirm their input. In addition, coffee drinkers were asked what type of coffee they usually drink, to which 
they could answer “Decaffeinated coffee (any type)”, “Instant coffee”, “Ground coffee (include espresso, filter 
etc)”, “Other type of coffee”, “Do not know” or “Prefer not to answer”. Amongst coffee drinkers we additionally 
excluded those who did not provide information on the type of coffee they usually drink. Coffee and tea intake 
were truncated at 20 cups per day.  
Decaffeinated coffee was considered to contain 3 mg of caffeine per cup, instant coffee 60 mg, ground coffee 85 
mg, and tea 30 mg23. Combined caffeine intake from both coffee and tea was calculated as the sum of the daily 
caffeine intake from coffee and tea from individuals who provided data on both.  
 
CAD and T2D prevalence and incidence in the UK Biobank 
Prevalence and incidence of CAD and T2D within UK Biobank were captured using self-reported data collected 
using the baseline-questionnaires and verbal interviews as per prior analysis24. Diagnoses were additionally 
captured using the Hospital Episode Statistics “Spell and Episode” category, which contains data on diagnoses 
made during hospital in-patient stay. We used both main and secondary diagnoses, coded according to the 
International Classification of Diseases (ICD) versions 9 and 1025. For CAD, we used ICD-9 codes 410, 412 and 
414, and ICD-10 codes I21-I25, Z951 and Z955. For T2D, we used ICD-9 code 250 and ICD-10 codes E10-E14. 
In addition we used surgical procedures that were recorded according to the Office of Population, Censuses and 
Surveys: Classification of interventions and Procedures (OPCS), version 4 coding26. For CAD, OPCS-4 codes 
K40-K46, K49, K50 and K75 were used. Incident cases that were based on self-reported diagnoses during follow-
up visits were included only if there were no events recorded according to ICD-9/ICD-10/OPCS 4 and only if the 
participant did not report this in the previous visit. If the participant was the same age as the reported age of 
diagnosis, the median date between the visit and their birthday was taken as date of event, and if the age of 
diagnosis was before the participants current age we took the median date of the year of the reported age of 
diagnosis counted from the participants birthday. If age of diagnosis was not available we took the median date 
between the visit of the first self-reported diagnosis and the previous visit. Participants with CAD or T2D at 
inclusion were excluded for the observational analyses of the respective disease. Follow-up for incident CAD, 
T2D and death due to these conditions was from inclusion until March 31, 2017 for participants from England, 
February 29, 2016 for Wales, and October 31, 2016 for Scotland. 
 
Genotyping and imputation in UK Biobank 
The genotyping process and arrays used in UK Biobank have been described elsewhere in more detail. Briefly, 
participants were genotyped using the custom Affymetrix UK Biobank Lung Exome Variant Evaluation (UK 
BiLEVE) AxiomTM (N=49,950) or Affymetrix UK Biobank AxiomTM array (N=438,427)27,28. The UK BiLEVE 
AxiomTM and UK Biobank AxiomTM arrays respectively have 807,411 and 820,927 single-nucleotide 
polymorphism (SNP), insertion and deletion markers with >95% common content28. Participants genotyped using 








never smokers)27. Genomic quality control of samples and variants, as well as imputation was performed by the 
Wellcome Trust Centre for Human Genetics, based on merged UK10K and 1000 Genomes phase 3 panels27,29. 
Participants were excluded if there was a mismatch between genetic and reported sex, if participants had high 
missingness or excess heterozygosity, or were not of white British descent. In total, from the 502,525 UK Biobank 
participants, 1,332 did not pass genomic quality control and 91,069 were not of white British descent. 
 
Genetic analyses 
All genetic analyses were adjusted for age, sex, genotyping array, and the first 30 principal components (PCs) to 
adjust for population stratification. We performed separate GWAS for inverse rank normalized combined caffeine 
intake, caffeine from coffee, and caffeine from tea. GWAS were performed using BOLT-LMM v2.3.1, which uses 
a linear mixed model that corrects for population structure and cryptic relatedness30. In total, 19,400,838 SNPs 
were included in the GWAS. To obtain a set of independent SNPs per phenotype, SNPs with P<5×10-8 were 
clumped together based on linkage disequilibrium (LD) R2>0.005 and 5-Mb distance using the clumping procedure 
integrated in PLINK version 1.9. To account for multiple testing of the 3 GWAS, we considered only SNPs with 
Bonferroni corrected P<1.67x10-8 (traditional GWAS significance threshold of 5x10-8/3) as statistically 
significant. This significance threshold is conservative, considering that our phenotypes are correlated with 
Spearman’s rank correlation coefficients between phenotype pairs ranging from r=-0.33 to 0.71 (Table S1).  
 
For each phenotype we consequently identified the sentinel SNP (defined as the most significant SNP in a 5-Mb 
region at either side of the SNP) at each locus. A locus was defined as a 1-Mb region at either side of the sentinel 
SNP. Similar to how the sentinel SNP per locus per phenotype was identified, a single sentinel SNP with the lowest 
P value per locus was identified across the sentinel SNPs of all three phenotypes for general caffeine intake. SNPs 
were excluded if the minor allele frequency (MAF) was <0.005 or the INFO score was below 0.3.  
 
Identification of candidate genes  
Candidate genes at each locus were prioritized based on 1) proximity, the nearest protein coding gene and any 
additional gene within 10kb of the sentinel SNP; 2) Data-driven Expression-Prioritized Integration for Complex 
Traits (DEPICT); and 3) expression quantitative trait locus (eQTL) genes in cis analyses. Summary information 
about candidate causal genes was obtained through queries in GeneCards. 
 
DEPICT analyses 
DEPICT has been described in detail previously31. Briefly, DEPICT systematically prioritizes likely causal genes 
at associated loci, and identifies tissue and cell types where genes from associated loci are highly expressed. 
DEPICT.v1.beta version rel194 1KG imputed GWAS was obtained from 
https://data.broadinstitute.org/mpg/depict/. DEPICT was run with default settings, using all variants at P<1.0x10-
5. Tissue and cell type enrichment found by DEPICT at FDR <0.05 were considered significant.  
 
eQTL analyses 
We applied a summary-data-based MR (SMR) approach in cis-eQTL data repositories from Genotype-Tissue 
Expression (GTEx) version 732, Brain-eMeta eQTL33, and blood eQTL from Westra34 and CAGE35. SMR, by 
default, was performed only in cis-regions. eQTL genes were considered as candidate causal genes if the top 
associated eQTL SNP achieved P<2.7x10-7 (P = 0.05/nSMRtests = [combined caffeine intake = 187,748; caffeine 
from coffee = 181,931; caffeine from tea = 182,971]), passed the HEterogeneity In Dependent Instruments 
(HEIDI) test with P>0.05, and were LD buddies (R2>0.8) with the queried caffeine intake SNP. HEIDI 
distinguishes pleiotropy from linkage by testing for heterogeneity in SMR estimates of SNPs in LD with the top-
associated cis-eQTL. In the case of pleiotropy, the gene expression and the trait of interest share the same SNP. 
Software for the SMR/HEIDI tests was downloaded from http://cnsgenomics.com/software/smr/#Download and 
eQTL catalogues from http://cnsgenomics.com/software/smr/#eQTLsummarydata. 
 
Associations between genetics with outcomes 
To gain insight in the potentially causal relationship between caffeine intake and CAD, we performed MR analyses 
on summary statistics data from the CARDIoGRAMplusC4D consortium as provided by Nikpay et al. in 123,504 
controls and 60,801 (33.0%) cases36. The CARDIoGRAMplusC4D data was obtained through MR Base. To assess 
the potentially causal relationship with T2D, MR analyses were performed on summary statistics data from the 
DIAGRAM consortium as reported by Scott et al., which included 132,532 controls and 26,676 cases (16.8%)37. 
Summary statistics data for DIAGRAM was downloaded from http://www.diagram-
consortium.org/downloads.html. Analyses were performed per caffeine intake trait using the lead SNPs at 
P<1.67x10-8. Proxies based on highest LD and position were used for SNPs that were not available in 
CARDIoGRAMplusC4D or DIAGRAM. SNPs were only replaced with proxies with R2>0.8, and were otherwise 








studies using the built-in function in the MR Base R package (TwoSampleMR). The association between 
genetically determined higher caffeine intake and CAD or T2D was assessed using a fixed-effects inverse-variance 
weighted (IVW) meta-analysis method which combines MR estimates for individual SNPs with the outcome. Odds 
ratios (OR) with 95%CI are presented for the MR outcomes. To maximize the likelihood of reporting true findings, 
α was set at 0.005 rather than 0.0539. Associations with P<0.05 were considered suggestively significant.  
 
Weak instrument bias 
The strength of the instruments (SNPs) per phenotype was assessed using the F-statistic, calculated as F=R2(nsample-
2)/(1-R2), where R2 is the proportion of variability in caffeine intake. An F-statistic >10 indicates relatively low 
risk of weak instrument bias in MR analyses40, which is essential to prevent violation of the ‘NO Measurement 
Error’ assumption. Additionally, potential weak instrument bias in MR-Egger regression analyses was assessed by 
calculating I2GX, which is the true variance of the SNP-exposure association. I2GX >95% indicates small uncertainty 
in the SNP-exposure association estimates and was considered low risk of measurement error41. 
 
Analyses for pleiotropy in MR  
In MR analyses, pleiotropy indicates multiple effects are exerted by a SNP, which could violate the assumption in 
MR analysis that the SNP only influences the outcome through the exposure of interest (here, caffeine). We applied 
multiple tests to investigate potential pleiotropy in our analyses. First, I2 index and Cochran’s Q statistic were 
determined. An I2 index >25% and Cochran’s Q P<0.05 were considered indicative of heterogeneity and thus 
pleiotropy42. In case of evidence of heterogeneity, each instrument can be allowed to have a (balanced) pleiotropic 
effect and a random effects IVW method can be applied43. MR-Egger, which in contrast to the IVW method 
assumes pleiotropic effects of the SNPs on the outcome are independent of their association with the exposure 
(caffeine), was performed as an additional test. If the MR-Egger intercept is zero, tested using P>0.05, this 
indicated there was evidence for absent pleiotropic bias, whereas deviations from zero indicate horizontal 
pleiotropy across the SNPs. If the InSIDE assumption, which assumes the association of SNPs with the exposure 
are independent of the direct pleiotropic effects of the SNP on the outcome, is satisfied, the coefficient from the 
MR-Egger regression is an estimate of the causal effect. We further assessed heterogeneity within the MR-Egger 
analysis using the Rücker’s Q’ statistic, and tested whether this differed (P<0.05) from Cochran’s Q (Q-Q’). A 
significant difference indicates the MR-Egger is the preferred method to study the association between the 
exposure and the outcome43.  Pleiotropy was further tested using the MR pleiotropy residual sum and outlier (MR-
PRESSO) test44, which compares the residuals for each SNP in the zero-intercept regression line of the SNP-
outcome estimate with the SNP-exposure estimate in the absence of pleiotropy. Hereby, pleiotropic effects can be 
detected and outliers identified. MR-PRESSO then re-analyses the association without the outliers, correcting for 
potential pleiotropic effects44. MR-Steiger filtering was performed to remove variants which are stronger 
associated with the outcome than the exposure45. To this end, the R2 for the exposure and outcome is calculated, 
after which variants with significantly lower R2 for the exposure than for the outcome are removed.  
 
Sensitivity analyses in MR 
We additionally performed several sensitivity analyses. First, weighted median MR analysis was performed, which 
allows up to 50% of the instruments to be invalid, in contrast to regular IVW analysis where absence of pleiotropic 
effects of the instruments is assumed. Next, weighted mode-based estimator MR analyses were performed to allow 
even larger numbers of SNPs to be invalid, but rather takes the overall MR result from the greatest number of valid 
SNPs with similar MR estimates46. The R packages TwoSampleMR version 0.4.22 












This research has been conducted using the UK Biobank Resource under Application Number 12006 and 15031.  
 
CARDIoGRAMplusC4D Consortium 
We used summary statistics data available in MR Base from the Coronary Artery Disease Genome wide 
Replication and Meta-analysis plus The Coronary Artery Disease (CARDIoGRAMplusC4D) consortium as 
published by Nikpay et al. in 201536. The CARDIoGRAMplusC4D cohort consisted of 123,504 controls and 
60,801 (33.0%) coronary artery disease cases.  
 
DIAGRAM consortium 
We used summary statistics data from the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) 
consortium as published by Scott et al. in 201737, downloaded from http://www.diagram-











Table S1. Spearman's rank correlation between phenotypical caffeine intake traits 
 
Combined daily caffeine intake Daily caffeine intake from coffee Daily caffeine intake from tea 
Combined daily caffeine intake 1 
  
Daily caffeine intake from coffee 0.7147 1 
 
Daily caffeine intake from tea 0.3071 -0.3319 1 









Table S2. Baseline characteristics for individuals included in the GWAS on combined caffeine intake, caffeine from coffee, or caffeine 
from tea 
Characteristic Combined Caffeine Caffeine from Coffee Caffeine from Tea 
Total, n 362,316 373,522 395,866 
Age, mean (SD), y 56.94 (8.00) 56.92 (8.01) 56.94 (7.99) 
Female 195,754 (54.0%) 201,463 (53.9%) 214,395 (54.2%) 
Daily caffeine intake, median (IQR), mg/day 
   
  Combined caffeine 205 (120-290) 205 (120-290) 205 (120-290) 
  Caffeine from coffee 60 (3-180) 85 (3-180) 60 (3-180) 
  Caffeine from tea 90 (60-150) 90 (60-150) 90 (60-150) 
Blood pressure, mean (SD), mm Hg 
   
  Systolic 133.75 (17.94) 133.76 (17.93) 133.73 (17.95) 
  Diastolic 82.13 (8.54) 82.14 (8.54) 82.12 (8.54) 
Active smoker 
   
  No 325,226 (89.8%) 335,025 (89.7%) 355,938 (89.9%) 
  Yes 37,090 (10.2%) 38,497 (10.3%) 39,928 (10.1%) 
BMI, mean (SD), kg/m2 27.43 (4.74) 27.43 (4.75) 27.41 (4.75) 
Weekly alcohol intake, median (IQR), UK units 9.60 (1.96-20.20) 9.60 (1.96-20.20) 9.60 (1.96-20.00) 
Hypertension 
   
  No 250,114 (69.0%) 257,966 (69.1%) 272,994 (69.0%) 
  Yes 112,202 (31.0%) 115,556 (30.9%) 122,872 (31.0%) 
Hyperlipidemia 
   
  No 291,798 (80.5%) 300,872 (80.6%) 318,841 (80.5%) 
  Yes 70,518 (19.5%) 72,650 (19.4%) 77,025 (19.5%) 








Table S3. Baseline characteristics per 60 mg of combined caffeine intake 
Characteristic 0 mg 1-60 mg 61-120 mg 121-180 mg 181-240 mg 241-300 mg 301-360 mg >360 mg 
Total, n 8,845 26,279 55,733 81,959 69,745 51,542 31,198 37,015 
Age, mean (SD), y 53.61 (8.33) 56.05 (8.28) 56.91 (8.12) 57.33 (7.99) 57.52 (7.85) 57.20 (7.84) 56.87 (7.80) 56.19 (7.94) 
Female 5,673 (64.1%) 16,185 (61.6%) 32,673 (58.6%) 46,430 (56.7%) 37,917 (54.4%) 26,289 (51.0%) 14,948 (47.9%) 15,639 (42.3%) 
Daily caffeine intake, median (IQR), mg/day 
        
  Combined caffeine 0 (0-0) 33 (15-60) 96 (90-120) 159 (150-180) 230 (210-240) 285 (270-300) 345 (330-360) 450 (420-540) 
  Caffeine from coffee 0 (0-0) 6 (0-15) 3 (0-60) 18 (0-85) 120 (60-170) 170 (120-240) 240 (170-300) 340 (255-425) 
  Caffeine from tea 0 (0-0) 30 (0-30) 90 (60-90) 120 (60-150) 120 (60-180) 120 (60-180) 90 (60-180) 120 (30-210) 
Blood pressure, mean (SD), mm Hg 
        
   Systolic 128.79 (17.62) 132.38 (18.11) 133.68 (18.19) 133.96 (18.18) 134.20 (17.91) 134.26 (17.72) 134.08 (17.56) 133.72 (17.44) 
   Diastolic 80.92 (8.87) 81.70 (8.70) 82.03 (8.58) 82.05 (8.56) 82.13 (8.47) 82.35 (8.44) 82.43 (8.50) 82.49 (8.50) 
Active smoker 
        
   No 8,235 (93.1%) 24,301 (92.5%) 52,154 (93.6%) 75,786 (92.5%) 63,530 (91.1%) 45,656 (88.6%) 26,631 (85.4%) 28,933 (78.2%) 
   Yes 610 (6.9%) 1,978 (7.5%) 3,579 (6.4%) 6,173 (7.5%) 6,215 (8.9%) 5,886 (11.4%) 4,567 (14.6%) 8,082 (21.8%) 
BMI, mean (SD), kg/m2 27.84 (5.77) 27.87 (5.23) 27.32 (4.82) 27.28 (4.69) 27.24 (4.57) 27.40 (4.53) 27.57 (4.65) 27.75 (4.75) 
Weekly alcohol intake, median (IQR), UK units 1.96 (1.00-12.40) 6.90 (1.60-17.90) 8.70 (1.96-19.20) 9.60 (1.96-19.20) 9.60 (2.00-20.20) 10.80 (2.66-21.30) 11.20 (2.90-22.40) 11.20 (1.96-23.20) 
Hypertension 
        
   No 6,542 (74.0%) 17,598 (67.0%) 37,359 (67.0%) 55,634 (67.9%) 48,329 (69.3%) 36,266 (70.4%) 22,152 (71.0%) 26,234 (70.9%) 
   Yes 2,303 (26.0%) 8,681 (33.0%) 18,374 (33.0%) 26,325 (32.1%) 21,416 (30.7%) 15,276 (29.6%) 9,046 (29.0%) 10,781 (29.1%) 
Hyperlipidemia 
        
   No 7,646 (86.4%) 20,773 (79.0%) 44,522 (79.9%) 65,591 (80.0%) 56,254 (80.7%) 41,857 (81.2%) 25,345 (81.2%) 29,810 (80.5%) 
   Yes 1,199 (13.6%) 5,506 (21.0%) 11,211 (20.1%) 16,368 (20.0%) 13,491 (19.3%) 9,685 (18.8%) 5,853 (18.8%) 7,205 (19.5%) 









Table S4. Baseline characteristics per 60 mg caffeine intake from coffee 
Characteristic 0 mg 1-60 mg 61-120 mg 121-180 mg 181-240 mg 24-300 mg1 301-360 mg >360 mg 
Total, n 85,680 100,079 61,866 49,884 22,315 24,478 15,473 13,747 
Age, mean (SD), y 55.88 (8.15) 57.95 (7.83) 57.25 (7.97) 57.15 (7.92) 56.85 (7.90) 56.36 (7.97) 56.31 (7.91) 55.35 (8.00) 
Female 49,810 (58.1%) 59,014 (59.0%) 32,525 (52.6%) 25,331 (50.8%) 10,745 (48.2%) 11,382 (46.5%) 6,944 (44.9%) 5,712 (41.6%) 
Daily caffeine intake, median (IQR), mg/day 
        
  Combined caffeine 150 (90-180) 129 (72-183) 210 (175-240) 260 (210-300) 300 (240-360) 330 (300-375) 390 (360-450) 540 (480-630) 
  Caffeine from coffee 0 (0-0) 15 (6-60) 120 (85-120) 180 (170-180) 240 (240-240) 300 (255-300) 360 (340-360) 480 (425-595) 
  Caffeine from tea 150 (90-180) 90 (60-150) 90 (60-150) 90 (30-120) 60 (0-120) 60 (0-90) 30 (0-90) 30 (0-90) 
Blood pressure, mean (SD), mm Hg 
        
  Systolic 132.74 (18.30) 133.78 (17.99) 134.17 (17.93) 134.13 (17.80) 135.10 (17.70) 134.02 (17.43) 134.24 (17.26) 133.47 (17.36) 
  Diastolic 81.90 (8.68) 81.79 (8.46) 82.26 (8.53) 82.29 (8.45) 82.87 (8.58) 82.50 (8.48) 82.69 (8.46) 82.61 (8.58) 
Active smoker 
        
  No 77,385 (90.3%) 92,972 (92.9%) 56,678 (91.6%) 45,213 (90.6%) 19,289 (86.4%) 20,972 (85.7%) 12,607 (81.5%) 9,909 (72.1%) 
  Yes 8,295 (9.7%) 7,107 (7.1%) 5,188 (8.4%) 4,671 (9.4%) 3,026 (13.6%) 3,506 (14.3%) 2,866 (18.5%) 3,838 (27.9%) 
BMI, mean (SD), kg/m2 27.50 (5.01) 27.41 (4.70) 27.08 (4.58) 27.19 (4.54) 27.95 (4.69) 27.52 (4.64) 27.93 (4.87) 28.08 (4.98) 
Weekly alcohol intake, median (IQR), UK units 6.40 (1.17-17.90) 8.00 (1.96-17.60) 11.20 (3.60-22.10) 12.00 (4.80-22.70) 11.50 (3.20-23.00) 12.60 (4.43-23.50) 12.30 (3.16-24.00) 11.00 (1.96-23.90) 
Hypertension 
        
  No 58,289 (68.0%) 66,870 (66.8%) 43,294 (70.0%) 35,409 (71.0%) 15,610 (70.0%) 17,743 (72.5%) 10,957 (70.8%) 9,794 (71.2%) 
  Yes 27,391 (32.0%) 33,209 (33.2%) 18,572 (30.0%) 14,475 (29.0%) 6,705 (30.0%) 6,735 (27.5%) 4,516 (29.2%) 3,953 (28.8%) 
Hyperlipidemia 
        
  No 69,397 (81.0%) 79,007 (78.9%) 50,233 (81.2%) 40,659 (81.5%) 18,025 (80.8%) 20,107 (82.1%) 12,464 (80.6%) 10,980 (79.9%) 
  Yes 16,283 (19.0%) 21,072 (21.1%) 11,633 (18.8%) 9,225 (18.5%) 4,290 (19.2%) 4,371 (17.9%) 3,009 (19.4%) 2,767 (20.1%) 








Table S5. Baseline characteristics per 60 mg caffeine intake from tea 
Characteristic 0 mg 1-60 mg 61-120 mg 121-180 mg >180 mg 
Total, n 60,199 87,981 119,872 85,705 42,109 
Age, mean (SD), y 55.81 (8.18) 56.63 (8.16) 57.49 (7.90) 57.29 (7.83) 56.94 (7.79) 
Female 33,935 (56.4%) 45,911 (52.2%) 65,987 (55.0%) 46,619 (54.4%) 21,943 (52.1%) 
Daily caffeine intake, median (IQR), mg/day 
     
  Combined caffeine 180 (12-300) 180 (72-270) 180 (120-270) 210 (162-270) 300 (240-385) 
  Caffeine from coffee 180 (12-300) 120 (15-240) 60 (3-170) 60 (0-120) 3 (0-85) 
  Caffeine from tea 0 (0-0) 60 (30-60) 90 (90-120) 150 (150-180) 240 (210-300) 
Blood pressure, mean (SD), mm Hg 
     
  Systolic 133.11 (17.83) 133.80 (17.94) 133.99 (17.99) 133.91 (18.03) 133.35 (17.84) 
  Diastolic 82.25 (8.68) 82.21 (8.60) 82.02 (8.48) 82.10 (8.50) 82.01 (8.48) 
Active smoker 
     
  No 52,157 (86.6%) 80,103 (91.0%) 110,804 (92.4%) 77,595 (90.5%) 35,279 (83.8%) 
  Yes 8,042 (13.4%) 7,878 (9.0%) 9,068 (7.6%) 8,110 (9.5%) 6,830 (16.2%) 
BMI, mean (SD), kg/m2 
28.16 (5.27) 27.25 (4.69) 27.15 (4.55) 27.37 (4.63) 27.48 (4.73) 
Weekly alcohol intake, log UK units 9.00 (1.96-20.60) 11.20 (3.20-22.40) 9.60 (2.06-19.80) 8.90 (1.96-19.20) 6.90 (1.17-18.40) 
Hypertension 
     
  No 41,492 (68.9%) 61,464 (69.9%) 82,497 (68.8%) 58,873 (68.7%) 28,668 (68.1%) 
  Yes 18,707 (31.1%) 26,517 (30.1%) 37,375 (31.2%) 26,832 (31.3%) 13,441 (31.9%) 
Hyperlipidemia 
     
  No 48,172 (80.0%) 71,307 (81.0%) 96,712 (80.7%) 68,990 (80.5%) 33,660 (79.9%) 
  Yes 12,027 (20.0%) 16,674 (19.0%) 23,160 (19.3%) 16,715 (19.5%) 8,449 (20.1%) 








Table S6. Unadjusted associations of phenotypic caffeine intake with new-onset coronary artery disease 
Caffeine Trait Caffeine intake (mg/day) N total N cases (%) Person-time at risk (years) Absolute risk Hazard Ratio 95% Confidence interval P value 
Combined intake 0 8,552 265 (3.10) 68222.505 3.10 1 Reference Reference 
 
1-60 24,983 1018 (4.07) 198905.92 4.07 1.32 (1.15-1.51) 6.27E-05 
 
61-120 53,067 2173 (4.09) 421662.78 4.09 1.33 (1.17-1.51) 1.22E-05 
 
121-180 78,040 3412 (4.37) 617136.57 4.37 1.43 (1.26-1.62) 2.52E-08 
 
181-240 66,669 2725 (4.09) 526813.63 4.09 1.34 (1.18-1.51) 7.05E-06 
 
241-300 49,359 2107 (4.27) 389466.51 4.27 1.40 (1.23-1.59) 2.89E-07 
 
301-360 29,858 1226 (4.11) 235711.7 4.11 1.34 (1.18-1.53) 1.40E-05 
 
>360 35,281 1755 (4.97) 277356.55 4.97 1.63 (1.44-1.86) 8.88E-14 
         
Coffee 0 81,341 3615 (4.44) 644426.54 4.44 1 Reference Reference 
 
1-60 95,254 4183 (4.39) 753153.67 4.39 0.99 (0.95-1.04) 0.67 
 
61-120 59,247 2266 (3.82) 468704.42 3.82 0.86 (0.82-0.91) 2.78E-08 
 
121-180 47,987 1767 (3.68) 380342.59 3.68 0.83 (0.78-0.88) 8.42E-11 
 
181-240 21,319 975 (4.57) 168465.82 4.57 1.03 (0.96-1.11) 0.39 
 
241-300 23,492 944 (4.02) 185517.36 4.02 0.91 (0.84-0.98) 8.00E-03 
 
301-360 14,826 637 (4.30) 117194.67 4.30 0.97 (0.89-1.06) 0.48 
 
>360 13,082 680 (5.20) 103020.73 5.20 1.18 (1.09-1.28) 8.54E-05 
         
Tea 0 57,433 2461 (4.28) 454797.51 4.28 1 Reference Reference 
 
1-60 84,260 3165 (3.76) 670336.26 3.76 0.87 (0.83-0.92) 3.38E-07 
 
61-120 114,525 4809 (4.20) 906479.66 4.20 0.98 (0.93-1.03) 0.43 
 
121-180 81,674 3620 (4.43) 643994.84 4.43 1.04 (0.99-1.09) 0.13 
 
>180 39,905 2012 (5.04) 313272.29 5.04 1.19 (1.12-1.26) 9.29E-09 









Table S7. Unadjusted associations of phenotypic caffeine intake with new-onset type 2 diabetes 
Caffeine Trait Caffeine intake (mg) N total N cases (%) Person-time at risk (years) Absolute risk Hazard Ratio 95% Confidence interval P value 
Combined intake 0 8,456 183 (2.16) 67917.769 2.16 1 Reference Reference  
1-60 25,012 651 (2.60) 200942.01 2.60 1.20 (1.02-1.42) 0.03  
61-120 53,431 1156 (2.16) 429276.93 2.16 1.00 (0.86-1.17) 0.99  
121-180 78,764 1516 (1.92) 631103.5 1.92 0.89 (0.77-1.04) 0.15  
181-240 67,123 1208 (1.80) 537016.45 1.80 0.84 (0.72-0.98) 0.02  
241-300 49,606 959 (1.93) 396529.11 1.93 0.90 (0.77-1.05) 0.19  
301-360 29,979 548 (1.83) 239606.07 1.83 0.85 (0.72-1.01) 0.06  
>360 35,347 761 (2.15) 282170.46 2.15 1.00 (0.85-1.18) 0.96   
       
Coffee 0 82,017 1946 (2.37) 657588.3 2.37 1 Reference Reference  
1-60 95,947 1938 (2.02) 768505.49 2.02 0.85 (0.80-0.91) 6.8E-07  
61-120 59,622 1046 (1.75) 477108.76 1.75 0.74 (0.69-0.80) 6.9E-15  
121-180 48,112 791 (1.64) 385341.27 1.64 0.69 (0.64-0.75) <1.0E-16  
181-240 21,358 451 (2.11) 171104.9 2.11 0.89 (0.80-0.99) 0.03  
241-300 23,542 426 (1.81) 188172.08 1.81 0.77 (0.69-0.85) 6.7E-07  
301-360 14,788 291 (1.97) 118443.97 1.97 0.83 (0.73-0.94) 3.2E-03  
>360 13,051 304 (2.33) 104416.4 2.33 0.98 (0.87-1.11) 0.81   
       
Tea 0 57,152 1402 (2.45) 457663.58 2.45 1 Reference Reference  
1-60 84,659 1602 (1.89) 680333.52 1.89 0.77 (0.71-0.82) 4.77E-13  
61-120 115,382 2084 (1.81) 925272.64 1.81 0.74 (0.69-0.79) <1.0E-16  
121-180 82,365 1627 (1.98) 658185.41 1.98 0.81 (0.75-0.87) 5.18E-09  
>180 40,311 885 (2.20) 321345.95 2.20 0.90 (0.83-0.98) 0.02 









Table S8. Multivariable adjusted associations of phenotypic caffeine intake with new-onset coronary artery disease 
Caffeine Trait Caffeine intake (mg) N total N cases (%) Person-time at risk (years) Absolute risk Hazard Ratio 95% Confidence interval P value 
Combined intake 0 8,552 265 (3.10) 68222.505 3.10 1 Reference Reference  
1-60 24,983 1018 (4.07) 198905.92 4.07 1.11 (0.97-1.27) 0.12  
61-120 53,067 2173 (4.09) 421662.78 4.09 1.07 (0.95-1.22) 0.27  
121-180 78,040 3412 (4.37) 617136.57 4.37 1.11 (0.98-1.26) 0.10  
181-240 66,669 2725 (4.09) 526813.63 4.09 1.01 (0.89-1.14) 0.90  
241-300 49,359 2107 (4.27) 389466.51 4.27 1.04 (0.91-1.18) 0.58  
301-360 29,858 1226 (4.11) 235711.7 4.11 0.98 (0.85-1.11) 0.72  
>360 35,281 1755 (4.97) 277356.55 4.97 1.12 (0.98-1.27) 0.10   
       
Coffee 0 81,341 3615 (4.44) 644426.54 4.44 1 Reference Reference  
1-60 95,254 4183 (4.39) 753153.67 4.39 0.92 (0.88-0.96) 3.89E-04  
61-120 59,247 2266 (3.82) 468704.42 3.82 0.81 (0.77-0.85) 7.99E-15  
121-180 47,987 1767 (3.68) 380342.59 3.68 0.77 (0.73-0.82) <1.0E-16  
181-240 21,319 975 (4.57) 168465.82 4.57 0.91 (0.85-0.98) 1.13E-02  
241-300 23,492 944 (4.02) 185517.36 4.02 0.84 (0.78-0.90) 1.04E-06  
301-360 14,826 637 (4.30) 117194.67 4.30 0.83 (0.76-0.90) 1.70E-05  
>360 13,082 680 (5.20) 103020.73 5.20 0.98 (0.91-1.07) 0.71   
       
Tea 0 57,433 2461 (4.28) 454797.51 4.28 1 Reference Reference  
1-60 84,260 3165 (3.76) 670336.26 3.76 0.87 (0.83-0.92) 3.78E-07  
61-120 114,525 4809 (4.20) 906479.66 4.20 0.96 (0.91-1.00) 7.20E-02  
121-180 81,674 3620 (4.43) 643994.84 4.43 0.99 (0.94-1.04) 0.64  
>180 39,905 2012 (5.04) 313272.29 5.04 1.07 (1.00-1.13) 3.56E-02 
Cox regression analyses adjusted for age at inclusion, sex, body mass index (kg/m2) at inclusion, active smoking, log-transformed weekly alcohol intake (UK units), and Townsend Deprivation Index. 60 mg caffeine is equivalent to the caffeine content of one cup of instant coffee or 2 cups of tea. Person-time follow up is 









Table S9. Multivariable adjusted associations of phenotypic of caffeine intake with new-onset type 2 diabetes 
Caffeine Trait Caffeine intake (mg) N total N cases (%) Person-time at risk (years) Absolute risk Hazard Ratio 95% Confidence interval P value 
Combined intake 0 8,456 183 (2.16) 67917.769 2.16 1 Reference Reference 
 
1-60 25,012 651 (2.60) 200942.01 2.60 1.20 (1.02-1.42) 0.03 
 
61-120 53,431 1156 (2.16) 429276.93 2.16 1.07 (0.91-1.25) 0.40 
 
121-180 78,764 1516 (1.92) 631103.5 1.92 0.94 (0.81-1.10) 0.45 
 
181-240 67,123 1208 (1.80) 537016.45 1.80 0.89 (0.76-1.04) 0.13 
 
241-300 49,606 959 (1.93) 396529.11 1.93 0.93 (0.79-1.09) 0.37 
 
301-360 29,979 548 (1.83) 239606.07 1.83 0.83 (0.71-0.99) 0.04 
 
>360 35,347 761 (2.15) 282170.46 2.15 0.91 (0.77-1.07) 0.23 
         
Coffee 0 82,017 1946 (2.37) 657588.3 2.37 1 Reference Reference 
 
1-60 95,947 1938 (2.02) 768505.49 2.02 0.88 (0.82-0.93) 4.46E-05 
 
61-120 59,622 1046 (1.75) 477108.76 1.75 0.81 (0.75-0.87) 4.87E-08 
 
121-180 48,112 791 (1.64) 385341.27 1.64 0.77 (0.71-0.84) 6.62E-10 
 
181-240 21,358 451 (2.11) 171104.9 2.11 0.84 (0.76-0.93) 1.07E-03 
 
241-300 23,542 426 (1.81) 188172.08 1.81 0.79 (0.71-0.87) 7.93E-06 
 
301-360 14,788 291 (1.97) 118443.97 1.97 0.76 (0.67-0.86) 1.57E-05 
 
>360 13,051 304 (2.33) 104416.4 2.33 0.84 (0.74-0.94) 3.80E-03 
         
Tea 0 57,152 1402 (2.45) 457663.58 2.45 1 Reference Reference 
 
1-60 84,659 1602 (1.89) 680333.52 1.89 0.91 (0.85-0.98) 1.25E-02 
 
61-120 115,382 2084 (1.81) 925272.64 1.81 0.86 (0.80-0.92) 1.59E-05 
 
121-180 82,365 1627 (1.98) 658185.41 1.98 0.89 (0.82-0.95) 1.02E-03 
 
>180 40,311 885 (2.20) 321345.95 2.20 0.90 (0.83-0.98) 1.67E-02 
Cox regression analyses adjusted for age at inclusion, sex, body mass index (kg/m2) at inclusion, active smoking, log-transformed weekly alcohol intake (UK units), and Townsend Deprivation Index. 60 mg caffeine is equivalent to the caffeine content of one cup of instant coffee or 2 cups of tea. Person-time follow up is 









Table S10. Associations of caffeine from coffee or tea additionally adjusted for caffeine intake from tea or coffee respectively 
Caffeine trait Outcome Caffeine intake (mg/day) N total N cases Person-time at risk (years) Hazard Ratio 95% Confidence interval P value 
Coffee CAD 0 80,659 3585 638979.73 1 Reference Reference 
  
1-60 93,173 4105 736562.39 0.93 0.89-0.98 3.49E-03 
  
61-120 57,946 2217 458418.04 0.82 0.78-0.87 4.92E-13 
  
121-180 46,065 1707 364964.26 0.79 0.75-0.84 1.33E-14 
  
181-240 20,183 939 159374.73 0.95 0.88-1.02 0.16 
  
241-300 21,967 898 173350.49 0.87 0.81-0.94 2.88E-04 
  
301-360 13,727 595 108434.36 0.86 0.78-0.94 7.88E-04 
  
>360 12,089 635 95192.156 1.03 0.94-1.12 0.58 
         
Tea CAD 0 55,825 2382 442052.98 1 Reference Reference 
  
1-60 79,764 2978 634422.94 0.86 0.81-0.91 5.56E-08 
  
61-120 103,981 4370 822745.06 0.94 0.89-0.99 0.02 
  
121-180 71,617 3189 564449.23 0.97 0.91-1.02 0.22 
  
>180 34,622 1762 271605.95 1.04 0.98-1.11 0.19 
         
Coffee T2D 0 81,341 1929 652143.91 1 Reference Reference 
  
1-60 93,878 1903 751852.25 0.86 0.81-0.92 4.79E-06 
  
61-120 58,318 1014 466693.64 0.79 0.73-0.85 1.29E-09 
  
121-180 46,186 758 369829.71 0.74 0.68-0.81 7.46E-12 
  
181-240 20,222 428 161941.97 0.80 0.72-0.89 4.48E-05 
  
241-300 22,000 388 175830.94 0.72 0.65-0.81 1.50E-08 
  
301-360 13,701 274 109674.18 0.72 0.63-0.82 9.16E-07 
  
>360 12,072 288 96595.711 0.80 0.71-0.91 8.75E-04 
         
Tea T2D 0 55,552 1357 444786.2 1 Reference Reference 
  
1-60 80,118 1502 643704.93 0.88 0.82-0.95 7.49E-04 
  
61-120 104,793 1898 840005.24 0.82 0.76-0.88 5.82E-08 
  
121-180 72,247 1430 577158.15 0.82 0.76-0.89 6.32E-07 
  
>180 35,008 795 278907.78 0.85 0.78-0.93 4.70E-04 
Adjusted for age at inclusion, sex, body mass index (kg/m2) at inclusion, active smoking, log-transformed weekly alcohol intake (UK units), and Townsend Deprivation Index. The analyses for caffeine from coffee were additionally adjusted for caffeine intake from tea, and the analyses for caffeine from tea were additionally 








Table S11. Associations of decaffeinated and caffeinated cups of coffee with new-onset coronary artery disease and type 2 diabetes                 
Group Outcome Cups of coffee N total N cases Person-time at risk (years) Hazard Ratio 95% Confidence interval P value 
Decaffeinated CAD 0 85,257 6,222 662436.76 1 Reference Reference 
  
1 16,340 1,116 127170.84 0.95 0.89-1.01 0.10 
  
2 14,932 928 116645.79 0.83 0.78-0.89 3.21E-07 
  
3 9,881 700 76817.509 0.96 0.89-1.04 0.28 
  
4 7,147 503 55563.823 0.92 0.84-1.01 0.07 
  
5 4,312 304 33483.425 0.93 0.83-1.05 0.24 
  
6 2,879 230 22278.00 1.02 0.90-1.17 0.75 
  
>6 2,351 176 18201.01 0.98 0.84-1.14 0.79 
         
Caffeinated CAD 0 85,257 6,222 662436.76 1 Reference Reference 
  
1 62,144 4,025 482864.61 0.83 0.80-0.87 <1.0E-16 
  
2 60,858 3,718 474437.8 0.77 0.74-0.80 <1.0E-16 
  
3 40,666 2,562 317174.8 0.80 0.76-0.84 <1.0E-16 
  
4 28,098 1,891 218703.22 0.83 0.79-0.87 1.84E-12 
  
5 16,594 1,165 128721.25 0.86 0.81-0.92 5.62E-06 
  
6 11,122 825 86165.836 0.85 0.79-0.92 1.56E-05 
  
>6 9,411 803 72635.775 0.97 0.90-1.04 0.38 
         
         
Decaffeinated T2D 0 85,257 4,689 669744.72 1 Reference Reference 
  
1 16,340 765 128765.31 0.94 0.87-1.01 0.10 
  
2 14,932 681 117636.71 0.89 0.82-0.96 0.00 
  
3 9,881 476 77887.652 0.92 0.83-1.01 0.08 
  
4 7,147 374 56086.719 0.93 0.84-1.04 0.20 
  
5 4,312 233 33805.93 0.92 0.80-1.05 0.20 
  
6 2,879 178 22489.786 1.04 0.89-1.20 0.63 
  
>6 2,351 149 18356.787 1.04 0.89-1.23 0.62 
         
Caffeinated T2D 0 85,257 4,689 669744.72 1 Reference Reference 
  
1 62,144 2,813 488247.68 0.89 0.85-0.93 1.77E-06 
  
2 60,858 2,691 479099.39 0.87 0.83-0.91 1.40E-08 
  
3 40,666 1,844 320263.23 0.89 0.84-0.93 1.17E-05 
  
4 28,098 1,456 220558.29 0.94 0.88-1.00 0.04 
  
5 16,594 916 129881.67 0.96 0.89-1.03 0.23 
  
6 11,122 639 87104.843 0.91 0.84-0.99 0.03 
  
>6 9,411 635 73355.381 1.05 0.97-1.14 0.24 








Table S12. GWAS top SNP results for combined caffeine intake at P<1.67x10-8 
SNP CHR hg19 EFAL NEFAL EF Freq BETA SE P value Genomic Band Nearest genes eQTL genes DEPICT genes 
rs2472297 15 75027880 C T 0.731645 -0.10487 0.002616 2.4E-351 q24.1 CYP1A1 
  
rs4410790 7 17284577 T C 0.364122 -0.08137 0.002412 1.50E-249 p21.1 AHR 
  
rs17685 7 75616105 G A 0.721471 -0.0408 0.002584 3.80E-56 q11.23 POR, STYXL1 AC005077.12 
 
rs56113850 19 41353107 T C 0.421755 -0.02649 0.002351 1.90E-29 q13.2 CYP2A6 
  
rs2231142 4 89052323 G T 0.886707 0.03913 0.00366 1.10E-26 q22.1 ABCG2 
  
7:73042302_GCTTT_G 7 73042302 GCTTT G 0.866226 -0.03591 0.003412 6.60E-26 q11.23 MLXIPL MLXIPL 
 
rs768283768 1 150701510 A AC 0.419751 0.024685 0.002462 1.20E-23 q21.3 HORMAD1, CTSS CERS2, CTSS, GOLPH3L, 
HORMAD1, SETDB1 
 
rs1260326 2 27730940 T C 0.391852 -0.02297 0.002377 4.20E-22 p23.3 GCKR 
  
rs6062679 20 62889991 T C 0.534615 -0.02278 0.002358 4.50E-22 q13.33 PCMTD2 PCMTD2 
 
rs199612805 22 24843991 T TGAAACCA 0.986403 0.095734 0.01012 3.10E-21 q11.23 SPECC1L-ADORA2A, ADORA2A 
  
rs9611527 22 41644428 G A 0.664286 0.019792 0.002466 1.00E-15 q13.2 CHADL, RANGAP1 RANGAP1 
 
rs139797380 6 137244957 C G 0.991601 0.106741 0.013575 3.70E-15 q23.3 PEX7, SLC35D3 
  
rs62332762 4 106143492 C T 0.597585 0.01828 0.002368 1.20E-14 q24 TET2 
  
rs117810762 10 135315795 G A 0.982023 -0.06827 0.008863 1.30E-14 q26.3 SPRN 
  
rs531431865 17 46165234 C CA 0.678686 -0.01854 0.002537 2.70E-13 q21.32 CBX1 
  
rs6265 11 27679916 C T 0.810755 0.021572 0.002964 3.40E-13 p14.1 BDNF 
  
rs489693 18 57882787 C A 0.67465 -0.01759 0.002478 1.30E-12 q21.32 MC4R 
  
rs12514566 5 7391462 G A 0.664698 0.017242 0.002456 2.20E-12 p15.31 ADCY2 
  
rs1490384 6 126851160 C T 0.501467 -0.01587 0.002323 8.30E-12 q22.32 CENPW 
  
1:174856749_TG_T 1 174856749 TG T 0.538714 0.016005 0.00235 9.70E-12 q25.1 RABGAP1L 
  
rs61141867 19 47556375 T TG 0.253635 -0.01842 0.002725 1.40E-11 q13.32 NPAS1, TMEM160 
  
rs4240624 8 9184231 G A 0.092461 0.02693 0.004012 1.90E-11 p23.1 PPP1R3B 
  
rs115454798 3 142092190 A G 0.871965 -0.02252 0.003491 1.10E-10 q23 XRN1 
  
16:18776851_G_GA 16 18776851 G GA 0.651439 0.017366 0.002727 1.90E-10 p12.3 RPS15A ARL6IP1 
 
rs12591786 15 60902512 C T 0.842038 0.020213 0.00323 3.90E-10 q22.2 RORA 
  
rs215601 7 32333921 A C 0.372618 0.01488 0.002404 6.00E-10 p14.3 PDE1C 
  
rs4418728 10 94839724 G T 0.550788 0.014384 0.002333 7.00E-10 q23.33 CYP26A1 
  
rs376877108 12 112020797 GTT G 0.201051 0.01783 0.002912 9.10E-10 q24.12 ATXN2 
  
rs78456557 3 123300686 C G 0.900201 -0.02364 0.00389 1.20E-09 q21.1 PTPLB 
  
6:108876096_CAAT_C 6 108876096 CAAT C 0.838739 0.018991 0.003165 2.00E-09 q21 FOXO3 
  
rs7105462 11 112912048 G A 0.40559 0.014163 0.002366 2.10E-09 q23.2 NCAM1 
  
rs2667773 15 77872191 A G 0.686772 0.014947 0.002506 2.50E-09 q24.3 LINGO1 
  
rs754177720 6 98555544 CA C 0.479652 -0.01384 0.002358 4.40E-09 q16.1 POU3F2 
  
20:35568001_AAAAG_A 20 35568001 AAAAG A 0.68498 0.014682 0.002513 5.20E-09 q11.23 SAMHD1 
  
rs12785227 10 65262685 A G 0.685798 0.014549 0.002507 6.50E-09 q21.3 REEP3 
  
3:50895869_ATAATAATAAT_A 3 50895869 ATAATAATAAT A 0.915367 0.028214 0.004864 6.60E-09 p21.2 DOCK3 
  
rs1228024 11 47951353 C A 0.340021 0.013965 0.002453 1.30E-08 p11.2 PTPRJ 
  
Sentinel SNPs per locus with P values <1.67x10-8. Nearest genes were the nearest protein coding gene and any additional gene within 10kb of the sentinel SNP. Abbreviations: SNP, single nucleotide polymorphism; CHR, chromosome; EFAL, effect allele; NEFAL, non-effect allele; EF Freq, effect allele frequency; SE, 









Table S13. GWAS top SNP results for caffeine intake from coffee at P<1.67x10-8 
SNP CHR hg19 EFAL NEFAL EF Freq BETA SE P value Genomic Band Nearest genes eQTL genes DEPICT genes 
rs2472297 15 75027880 C T 0.731859 -0.06521 0.002587 3.10E-140 q24.1 CYP1A1 
  
rs4410790 7 17284577 T C 0.364412 -0.05171 0.002384 2.80E-104 p21.1 AHR 
  
rs1057868 7 75615006 C T 0.714413 -0.02445 0.002536 5.50E-22 q11.23 POR 
  
rs201399553 16 53829963 T TTC 0.594033 -0.02253 0.002377 2.60E-21 q12.2 FTO 
  
rs56113850 19 41353107 T C 0.421821 -0.02071 0.002323 4.90E-19 q13.2 CYP2A6 
  
rs11127048 2 27752463 G A 0.381191 -0.01997 0.002398 8.10E-17 p23.3 GCKR 
  
rs66723169 18 57808978 C A 0.769043 -0.02249 0.002732 1.80E-16 q21.32 MC4R 
  
rs34060476 7 73037956 A G 0.865581 -0.02519 0.003365 7.10E-14 q11.23 MLXIPL MLXIPL 
 
rs181251778 22 24901968 A G 0.986146 0.072648 0.009834 1.50E-13 q11.23 UPB1 
  
rs531431865 17 46165234 C CA 0.678648 -0.0171 0.002507 9.00E-12 q21.32 CBX1 
  
rs7571970 2 646849 T C 0.172823 -0.02076 0.003047 9.40E-12 p25.3 TMEM18 
  
rs1327259 6 51177811 A G 0.614152 0.015707 0.002365 3.10E-11 p12.2 PKHD1 
  
rs6063085 20 45840459 A C 0.625251 -0.01571 0.00237 3.40E-11 q13.12 ZMYND8 
  
rs2726513 4 106217358 G T 0.587077 0.015301 0.002347 7.00E-11 q24 TET2 
  
rs4615895 1 96274668 G A 0.259574 -0.01705 0.002627 8.60E-11 p21.3 TMEM56-RWDD3 
  
rs139937261 17 17585130 C CG 0.487688 -0.01491 0.002304 9.80E-11 p11.2 RAI1 
  
rs2298527 11 112851961 G C 0.405568 0.014947 0.002336 1.60E-10 q23.2 NCAM1 
  
rs35198275 3 50536092 A G 0.865693 0.020797 0.003387 8.20E-10 p21.31 CACNA2D2 
  
rs12514566 5 7391462 G A 0.664625 0.014831 0.002428 1.00E-09 p15.31 ADCY2 
  
rs6893807 5 87965021 A G 0.843563 -0.01916 0.003159 1.30E-09 q14.3 MEF2C 
  
rs2521501 15 91437388 A T 0.677316 0.014916 0.002472 1.60E-09 q26.1 FES, MAN2A2 FES 
 
rs768283768 1 150701510 A AC 0.419823 0.014214 0.002434 5.20E-09 q21.3 HORMAD1, CTSS CTSS, GOLPH3L, HORMAD1 
 
rs76881016 10 134196286 A G 0.928496 -0.02584 0.004453 6.60E-09 q26.3 LRRC27 
  
rs117810762 10 135315795 G A 0.982047 -0.05011 0.008765 1.10E-08 q26.3 SPRN 
  
Sentinel SNPs per locus with P values <1.67x10-8. Nearest genes were the nearest protein coding gene and any additional gene within 10kb of the sentinel SNP. Abbreviations: SNP, single nucleotide polymorphism; CHR, chromosome; EFAL, effect allele; NEFAL, non-effect allele; EF Freq, effect allele frequency; SE, 









Table S14. GWAS top SNP results for caffeine intake from tea at P<1.67x10-8 
SNP CHR hg19 EFAL NEFAL EF Freq BETA SE P value Genomic Band Nearest genes eQTL genes DEPICT genes 
rs2472297 15 75027880 C T 0.732806 -0.05411 0.002521 3.30E-102 q24.1 CYP1A1 
 
SIN3A 
rs4410790 7 17284577 T C 0.36537 -0.04033 0.00232 1.10E-67 p21.1 AHR 
  
rs9624470 22 24820268 G A 0.419254 -0.02534 0.002272 6.80E-29 q11.23 SPECC1L, SPECC1L-ADORA2A, ADORA2A UPB1 
 
rs17685 7 75616105 G A 0.721688 -0.02391 0.002488 7.20E-22 q11.23 POR,STYXL1 
  
rs2465018 6 51241140 G A 0.769413 -0.02211 0.002666 1.10E-16 p12.2 PKHD1 
  
rs1481012 4 89039082 A G 0.887297 0.026005 0.003536 1.90E-13 q22.1 ABCG2 
  
rs56188862 1 174189269 T C 0.614947 0.016829 0.002297 2.40E-13 q25.1 RABGAP1L 
  
rs73053413 12 11329548 C T 0.836535 0.021681 0.003021 7.10E-13 p13.2 PRR4, TAS2R14, TAS2R42 PRR4, TAS2R15 
 
rs140775622 20 62962869 C T 0.830545 -0.02262 0.003207 1.80E-12 q13.33 PCMTD2 
  
rs4817505 21 34343828 T C 0.607874 -0.01512 0.002292 4.20E-11 q22.11 OLIG2 
 
OLIG2 
rs192084998 5 152077481 G A 0.703764 0.015836 0.002458 1.20E-10 q33.1 NMUR2 
  
rs10741694 11 16286183 T C 0.372823 -0.01474 0.002312 1.80E-10 p15.1 SOX6 
 
SOX6 
rs132919 22 41809903 G C 0.22639 -0.01708 0.002697 2.40E-10 q13.2 TEF 
 
TEF, ZC3H7B, SREBF2 
rs12591786 15 60902512 C T 0.842256 0.019576 0.003109 3.00E-10 q22.2 RORA 
  
rs11204711 1 150682115 A G 0.616497 -0.01444 0.002336 6.40E-10 q21.3 HORMAD1 GOLPH3L, HORMAD1 SETDB1, RPRD2 
rs11022752 11 13307622 A G 0.730907 -0.01535 0.002525 1.20E-09 p15.2 ARNTL 
  
rs141180025 7 39295736 CT C 0.391273 -0.01399 0.002335 2.10E-09 p14.1 POU6F2 
  
rs2117137 3 89525505 A G 0.594554 -0.01349 0.002273 2.90E-09 p11.1 EPHA3 
  
rs62534435 9 7042938 C G 0.796528 -0.01629 0.002776 4.40E-09 p24.1 KDM4C 
  
rs28429148 16 53798319 G A 0.565413 0.013189 0.002288 8.20E-09 q12.2 FTO 
  
rs139797380 6 137244957 C G 0.991607 0.075145 0.013059 8.70E-09 q23.3 PEX7, SLC35D3 
  
rs199602679 16 63031361 G GT 0.783938 -0.01603 0.0028 1.00E-08 q21 CDH8 
  
rs145755097 3 50254188 C CTTTGT 0.852979 -0.01849 0.003258 1.40E-08 p21.31 GNAI2 
 
RBM5 
rs77476394 1 26757610 CTAAA C 0.208732 -0.01572 0.002785 1.60E-08 p36.11 LIN28A, DHDDS 
  
Sentinel SNPs per locus with P values <1.67x10-8. Nearest genes were the nearest protein coding gene and any additional gene within 10kb of the sentinel SNP. Abbreviations: SNP, single nucleotide polymorphism; CHR, chromosome; EFAL, effect allele; NEFAL, non-effect allele; EF Freq, effect allele frequency; SE, 









Table S15. GWAS SNP results over all caffeine traits at P<1.67x10-8 based on the lowest P value 











































rs77476394 1 26757610 
CTAA
A 


























1 2 0.340 0.986 0.014 0.002 
1.30
E-08 
0.340 0.986 0.007 0.002 
2.60E
-03 
0.340 0.986 0.008 0.002 
1.00E
-03 







































0.929 1.000 0.004 0.004 
3.70E
-01 





1 5 0.686 0.997 0.015 0.003 
6.50
E-09 
0.686 0.997 0.006 0.002 
1.30E
-02 













1 6 0.685 0.989 0.015 0.003 
5.20
E-09 
0.685 0.989 0.011 0.002 
4.60E
-06 
0.685 0.989 0.006 0.002 
1.90E
-02 









































































1 10 0.687 0.995 0.015 0.003 
2.50
E-09 
0.687 0.995 0.010 0.002 
3.40E
-05 
0.687 0.995 0.001 0.002 
6.40E
-01 




























1 12 0.839 0.990 0.019 0.003 
2.00
E-09 
0.839 0.990 0.012 0.003 
7.10E
-05 
0.839 0.990 0.009 0.003 
2.70E
-03 
rs2521501 15 91437388 A T 0.677 0.983 0.015 0.002 
1.60E-
09 
Coffee 1 13 0.677 0.983 0.010 0.002 
4.80
E-05 



























0.844 0.997 0.007 0.003 
2.60E
-02 























































1 17 0.201 0.987 0.018 0.003 
9.10
E-10 
0.201 0.987 0.007 0.003 
9.80E
-03 
0.201 0.987 0.013 0.003 
3.00E
-06 
rs35198275 3 50536092 A G 0.866 0.982 0.021 0.003 
8.20E-
10 
Coffee 1 20 0.866 0.982 0.019 0.003 
2.40
E-08 


















Tea 0 20 0.853 0.935 0.000 0.003 
8.90
E-01 





















0 20 0.915 0.735 0.028 0.005 
6.60
E-09 
0.915 0.735 0.022 0.005 
5.10E
-06 
0.915 0.735 0.002 0.005 
6.60E
-01 





1 21 0.551 0.999 0.014 0.002 
7.00
E-10 
0.551 0.999 0.006 0.002 
1.10E
-02 
0.551 0.999 0.010 0.002 
2.90E
-06 





1 22 0.373 0.998 0.015 0.002 
6.00
E-10 
0.373 0.998 0.009 0.002 
8.50E
-05 
0.373 0.998 0.007 0.002 
1.20E
-03 
rs12591786 15 60902512 C T 0.842 0.967 0.020 0.003 
3.00E-
10 
Tea 1 24 0.842 0.967 0.020 0.003 
3.90
E-10 
0.842 0.967 0.006 0.003 
7.40E
-02 










1 25 0.651 0.797 0.017 0.003 
1.90
E-10 
0.652 0.797 0.011 0.003 
4.50E
-05 
0.651 0.797 0.008 0.003 
2.20E
-03 









































































rs2298527 11 112851961 G C 0.406 0.996 0.015 0.002 
1.60E-
10 
Coffee 1 28 0.406 0.996 0.014 0.002 
2.40
E-09 














0 28 0.406 0.993 0.014 0.002 
2.10
E-09 









rs192084998 5 152077481 G A 0.704 0.989 0.016 0.002 
1.20E-
10 









0.704 0.989 0.016 0.002 
1.20E
-10 












































0.488 0.988 0.006 0.002 
7.60E
-03 


















0.260 0.991 0.005 0.003 
5.00E
-02 







































0.625 1.000 0.008 0.002 
8.40E
-04 





1 35 0.092 0.999 0.027 0.004 
1.90
E-11 
0.092 0.999 0.016 0.004 
6.40E
-05 
0.092 0.999 0.013 0.004 
5.90E
-04 












































0.174 0.990 0.007 0.003 
2.00E
-02 































1 40 0.665 0.998 0.017 0.002 
2.20
E-12 
0.665 0.998 0.015 0.002 
1.00E
-09 
0.664 0.998 0.004 0.002 
7.60E
-02 
rs73053413 12 11329548 C T 0.837 0.997 0.022 0.003 
7.10E-
13 









0.837 0.997 0.022 0.003 
7.10E
-13 





1 42 0.811 1.000 0.022 0.003 
3.40
E-13 
0.811 1.000 0.015 0.003 
5.60E
-07 
0.811 1.000 0.012 0.003 
3.20E
-05 


























rs56188862 1 174189269 T C 0.615 0.998 0.017 0.002 
2.40E-
13 
Tea 1 46 0.615 0.998 0.015 0.002 
5.10
E-10 
0.615 0.998 0.001 0.002 
7.80E
-01 










0 46 0.539 0.980 0.016 0.002 
9.70
E-12 
0.538 0.980 0.003 0.002 
2.50E
-01 
0.539 0.980 0.015 0.002 
5.90E
-11 































1 50 0.598 0.998 0.018 0.002 
1.20
E-14 
0.598 0.998 0.015 0.002 
1.20E
-10 
0.598 0.998 0.005 0.002 
3.80E
-02 
rs2726513 4 106217358 G T 0.587 0.984 0.015 0.002 
7.00E-
11 
Coffee 0 50 0.587 0.984 0.018 0.002 
2.60
E-14 
0.587 0.984 0.015 0.002 
7.00E
-11 
0.587 0.984 0.004 0.002 
1.00E
-01 





1 52 0.992 0.867 0.107 0.014 
3.70
E-15 
0.992 0.867 0.056 0.013 
2.60E
-05 
0.992 0.867 0.075 0.013 
8.70E
-09 





1 54 0.664 0.994 0.020 0.002 
1.00
E-15 
0.664 0.994 0.009 0.002 
1.70E
-04 
0.664 0.994 0.015 0.002 
3.60E
-10 










































0.769 0.992 0.002 0.003 
3.60E
-01 




































































































rs1327259 6 51177811 A G 0.614 0.992 0.016 0.002 
3.10E-
11 
Coffee 0 58 0.614 0.992 0.004 0.002 
1.10
E-01 



























0.594 0.965 0.011 0.002 
4.30E
-06 
rs28429148 16 53798319 G A 0.565 0.970 0.013 0.002 
8.20E-
09 












0.565 0.970 0.013 0.002 
8.20E
-09 









































































































1 67 0.420 0.913 0.025 0.002 
1.20
E-23 
0.420 0.913 0.014 0.002 
5.20E
-09 
0.420 0.913 0.014 0.002 
2.80E
-09 




















































































1 71 0.887 1.000 0.039 0.004 
1.10
E-26 
0.887 1.000 0.019 0.004 
1.10E
-07 
0.886 1.000 0.026 0.004 
2.40E
-13 
rs1481012 4 89039082 A G 0.887 0.994 0.026 0.004 
1.90E-
13 
Tea 0 71 0.888 0.994 0.039 0.004 
2.70
E-26 
0.888 0.994 0.019 0.004 
2.00E
-07 
0.887 0.994 0.026 0.004 
1.90E
-13 





















rs199612805 22 24843991 T 
TGAA
ACCA 





0 74 0.986 0.984 0.096 0.010 
3.10
E-21 
0.986 0.984 0.073 0.010 
2.40E
-13 
0.986 0.984 0.035 0.010 
3.10E
-04 
rs181251778 22 24901968 A G 0.986 0.992 0.073 0.010 
1.50E-
13 
Coffee 0 74 0.986 0.992 0.093 0.010 
7.00
E-21 
0.986 0.992 0.073 0.010 
1.50E
-13 
0.986 0.992 0.034 0.010 
3.30E
-04 

































































































































Sentinel SNPs at each locus over all traits combined based on lowest P value are indicated by a 1 in the LOCUS column. Non-sentinel SNPs are indicated by a 0 in the LOCUS column. The trait corresponding with the SNP’s lowest P value is indicated in the Origin column. Details for each SNP are provided for all three traits. 









Table S16. Previously reported SNPs associated with caffeine intake or coffee consumption 
Study Author Year PMID Population SNPs Chr hg19 EFAL/
NEFA
L 





Sentinel SNP GWAS 
Non-additive genome-wide association 
scan reveals a new gene associated 
with habitual coffee consumption. 
Pirastu 2016 27561104 Italian rs2216084 6 107553312 T/C 0.082 
(0.014) 




     
rs6942255 6 107555018 A/G 0.082 
(0.014) 




     
rs7745311 6 107565060 C/T 0.082 
(0.014) 




     
rs7754744 6 107551281 G/A 0.082 
(0.014) 




     
rs9386630 6 107562914 G/T 0.082 
(0.014) 




Genome-wide meta-analysis identifies 








rs6968554 7 17287106 A/G -0.07 
(0.01) 




rs4410790 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea 
     




rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      




rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      
rs4410790 7 17284577 T/C -0.14 
(0.01) 




rs4410790 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      
rs7800944 7 73035857 T/C -0.05 
(0.01) 







Caffeine from Coffee      




rs17685 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea 
Genome-wide association analysis of 
coffee drinking suggests association 
with CYP1A1/CYP1A2 and NRCAM 
Amin 2012 21876539 Northern 
European 






rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      






rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      






rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      






Sequence variants at CYP1A1–
CYP1A2 and AHR associate with 
coffee consumption 





rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      





rs4410790 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea 
A genome-wide association study in 
the Japanese population identifies the 
12q24 locus for habitual coffee 
consumption: The J-MICC Study. 
Nakagawa-
Senda 
2018 29367735 Japanese rs2074356 12 112645401 A/G 0.1920 
(0.0234) 
2.20E-16 NA Yes, not 
sentinel SNP 








Study Author Year PMID Population SNPs Chr hg19 EFAL/
NEFA
L 





Sentinel SNP GWAS 
Genome-wide meta-analysis identifies 
regions on 7p21 (AHR) and 15q24 
(CYP1A2) as determinants of habitual 
caffeine consumption. 
Cornelis 2011 21490707 European 
descent in 
the US 
rs4410790 7 17284577 T/C -0.15 
(0.02) 
2.40E-19 NA Yes, sentinel 
SNP 
rs4410790 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea 
     
rs2470893 15 75019449 T/C 0.12 (0.02) 5.20E-14 NA Yes, not 
sentinel SNP 
rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea 
Genome-wide association study of 
caffeine metabolites provides new 
insights to caffeine metabolism and 
dietary caffeine-consumption behavior  
Cornelis 2016 27702941 European 
ancestry 




rs4410790 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea 
     




rs4410790 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      




rs4410790 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      




rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      




rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      




rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      




rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea      




rs2472297 Caffeine combined, 
Caffeine from Coffee, 
Caffeine from Tea 








Table S17. Cups of different coffee type relating to one unit change in genetically determined caffeine intake from coffee 
 
Type of coffee usually drunk N Median caffeine intake (IQR) Beta SE 95% confidence interval P value 
Decaffeinated coffee 58,060 6 (3-12) 1.47 0.10 1.26-1.67 <0.001 
Instant coffee 167,923 180 (60-240) 2.10 0.06 1.97-2.22 <0.001 
Ground coffee 61,859 170 (85-255) 1.73 0.08 1.57-1.90 <0.001 









Table S18. DEPICT tissue and cell type enrichment results for caffeine intake SNPs 
 
Combined Caffeine intake Caffeine from Coffee Caffeine from Tea 














A08.186.211.132 Brain Stem Nervous System Central Nervous 
System 
2.78E-03 <0.05 8.96E-03 >=0.20 9.64E-04 <0.01 
A08.186.211.132.810.428.200 Cerebellum Nervous System Central Nervous 
System 
4.60E-04 <0.05 6.13E-03 >=0.20 3.65E-04 <0.01 
A08.186.211.865.428 Metencephalon Nervous System Central Nervous 
System 
7.06E-04 <0.05 5.21E-03 >=0.20 3.87E-04 <0.01 
A09.371.729 Retina Sense Organs Eye 3.40E-03 <0.05 4.12E-03 >=0.20 5.80E-04 <0.01 
A08.186.211.865 Rhombencephalon Nervous System Central Nervous 
System 
7.06E-04 <0.05 5.21E-03 >=0.20 3.87E-04 <0.01 
A08.186.211 Brain Nervous System Central Nervous 
System 
0.04 >=0.20 6.83E-03 >=0.20 8.76E-04 <0.01 
A08.186 Central Nervous System Nervous System Central Nervous 
System 
0.04 >=0.20 6.53E-03 >=0.20 8.67E-04 <0.01 
A08.186.211.464.405 Hippocampus Nervous System Central Nervous 
System 
8.37E-03 <0.20 2.96E-03 >=0.20 1.28E-03 <0.05 
A08.186.211.464 Limbic System Nervous System Central Nervous 
System 
0.02 >=0.20 3.22E-03 >=0.20 2.40E-03 <0.05 
A08.186.211.730.885.287.500.57
1.735 
Visual Cortex Nervous System Central Nervous 
System 
0.01 <0.20 0.01 >=0.20 8.99E-03 <0.20 
A08.186.211.730.885.287.500 Cerebral Cortex Nervous System Central Nervous 
System 
0.02 >=0.20 4.25E-03 >=0.20 3.26E-03 <0.20 
A08.186.211.730.885.287 Cerebrum Nervous System Central Nervous 
System 
0.02 >=0.20 6.24E-03 >=0.20 3.78E-03 <0.20 
A08.186.211.464.710.225 Entorhinal Cortex Nervous System Central Nervous 
System 
0.03 >=0.20 4.03E-03 >=0.20 3.14E-03 <0.20 
A10.272.497 Epidermis Tissues Epithelium 0.27 >=0.20 0.84 >=0.20 0.01 <0.20 
A11.872.653 Neural Stem Cells Cells Stem Cells 0.22 >=0.20 0.18 >=0.20 3.63E-03 <0.20 
A08.186.211.730.885.287.500.57
1 
Occipital Lobe Nervous System Central Nervous 
System 
0.01 >=0.20 0.01 >=0.20 7.79E-03 <0.20 
A08.186.211.464.710 Parahippocampal Gyrus Nervous System Central Nervous 
System 
0.03 >=0.20 4.03E-03 >=0.20 3.14E-03 <0.20 
A08.186.211.730 Prosencephalon Nervous System Central Nervous 
System 
0.03 >=0.20 8.28E-03 >=0.20 6.68E-03 <0.20 
A08.186.211.730.885 Telencephalon Nervous System Central Nervous 
System 
0.02 >=0.20 6.47E-03 >=0.20 3.80E-03 <0.20 
A08.186.211.730.885.287.500.86
3 
Temporal Lobe Nervous System Central Nervous 
System 
0.04 >=0.20 5.27E-03 >=0.20 4.01E-03 <0.20 
A06.407.071 Adrenal Glands Endocrine System Endocrine Glands 2.35E-03 <0.05 0.16 >=0.20 0.35 >=0.20 
A06.407.071.140 Adrenal Cortex Endocrine System Endocrine Glands 4.35E-03 <0.20 0.25 >=0.20 0.4 >=0.20 
A10.165.114.830.500 Abdominal Fat Tissues Connective Tissue 0.68 >=0.20 0.56 >=0.20 0.26 >=0.20 
A11.329.114 Adipocytes Cells Connective Tissue Cells 0.45 >=0.20 0.81 >=0.20 0.66 >=0.20 
A10.165.114 Adipose Tissue Tissues Connective Tissue 0.61 >=0.20 0.59 >=0.20 0.28 >=0.20 
A10.165.114.830 Adipose Tissue  White Tissues Connective Tissue 0.6 >=0.20 0.55 >=0.20 0.23 >=0.20 
A05.360.319.114 Adnexa Uteri Urogenital System Genitalia 0.14 >=0.20 0.37 >=0.20 0.24 >=0.20 
A11.872.040 Adult Stem Cells Cells Stem Cells 0.44 >=0.20 0.88 >=0.20 0.62 >=0.20 
A09.371.060 Anterior Eye Segment Sense Organs Eye 0.78 >=0.20 0.98 >=0.20 0.36 >=0.20 
A11.063 Antibody Producing Cells Cells Antibody-Producing 
Cells 
0.79 >=0.20 0.08 >=0.20 0.98 >=0.20 
A11.066 Antigen Presenting Cells Cells Antigen-Presenting 
Cells 









Combined Caffeine intake Caffeine from Coffee Caffeine from Tea 














A07.541.510.110 Aortic Valve Cardiovascular System Heart 0.14 >=0.20 0.35 >=0.20 0.11 >=0.20 
A07.231.114 Arteries Cardiovascular System Blood Vessels 0.86 >=0.20 0.99 >=0.20 0.53 >=0.20 
A07.541.358.100 Atrial Appendage Cardiovascular System Heart 0.3 >=0.20 0.13 >=0.20 0.58 >=0.20 
A11.118.637.555.567.562 B Lymphocytes Cells Blood Cells 0.79 >=0.20 0.08 >=0.20 0.98 >=0.20 
A08.186.211.730.885.287.249 Basal Ganglia Nervous System Central Nervous 
System 
0.13 >=0.20 0.35 >=0.20 0.1 >=0.20 
A15.145 Blood Hemic and Immune 
Systems 
Blood 0.92 >=0.20 0.08 >=0.20 0.93 >=0.20 
A15.145.229 Blood Cells Hemic and Immune 
Systems 
Blood 0.97 >=0.20 0.08 >=0.20 0.94 >=0.20 
A15.145.229.188 Blood Platelets Hemic and Immune 
Systems 
Blood 0.86 >=0.20 0.13 >=0.20 1 >=0.20 
A07.231 Blood Vessels Cardiovascular System Blood Vessels 0.95 >=0.20 0.98 >=0.20 0.87 >=0.20 
A02.835.232 Bone and Bones Musculoskeletal System Skeleton 0.98 >=0.20 0.21 >=0.20 0.95 >=0.20 
A15.382.216 Bone Marrow Hemic and Immune 
Systems 
Immune System 0.97 >=0.20 0.18 >=0.20 0.95 >=0.20 
A15.378.316 Bone Marrow Cells Hemic and Immune 
Systems 
Hematopoietic System 1 >=0.20 0.48 >=0.20 0.93 >=0.20 
A02.835.232.043 Bones of Lower Extremity Musculoskeletal System Skeleton 0.76 >=0.20 0.97 >=0.20 0.41 >=0.20 
A02.165 Cartilage Musculoskeletal System Cartilage 0.2 >=0.20 0.73 >=0.20 0.62 >=0.20 
A15.145.229.637.555.567.569.20
0 
CD4 Positive T Lymphocytes Hemic and Immune 
Systems 
Blood 0.29 >=0.20 0.11 >=0.20 0.41 >=0.20 
A03.556.249.249.209 Cecum Digestive System Gastrointestinal Tract 0.31 >=0.20 0.57 >=0.20 0.71 >=0.20 
A02.835.232.834.151 Cervical Vertebrae Musculoskeletal System Skeleton 0.36 >=0.20 0.75 >=0.20 0.46 >=0.20 
A05.360.319.679.256 Cervix Uteri Urogenital System Genitalia 0.74 >=0.20 0.46 >=0.20 0.96 >=0.20 
A11.329.171 Chondrocytes Cells Connective Tissue Cells 0.53 >=0.20 0.9 >=0.20 0.89 >=0.20 
A10.615.284.473 Chorion Tissues Membranes 0.64 >=0.20 0.97 >=0.20 0.93 >=0.20 
A10.165.450.300 Cicatrix Tissues Connective Tissue 0.86 >=0.20 0.81 >=0.20 0.66 >=0.20 
A03.556.249.249.356 Colon Digestive System Gastrointestinal Tract 0.28 >=0.20 0.78 >=0.20 0.69 >=0.20 
A03.556.249.249.356.668 Colon  Sigmoid Digestive System Gastrointestinal Tract 0.31 >=0.20 0.45 >=0.20 0.56 >=0.20 
A09.371.337.168 Conjunctiva Sense Organs Eye 0.76 >=0.20 0.98 >=0.20 0.36 >=0.20 
A10.165 Connective Tissue Tissues Connective Tissue 0.98 >=0.20 0.22 >=0.20 0.95 >=0.20 
A11.329 Connective Tissue Cells Cells Connective Tissue Cells 0.98 >=0.20 0.98 >=0.20 0.84 >=0.20 
A08.186.211.730.885.287.249.48
7 
Corpus Striatum Nervous System Central Nervous 
System 
0.09 >=0.20 0.47 >=0.20 0.09 >=0.20 
A06.407.312.497.535.300.500 Cumulus Cells Endocrine System Endocrine Glands 0.09 >=0.20 0.36 >=0.20 0.99 >=0.20 
A15.382.812.260 Dendritic Cells Hemic and Immune 
Systems 
Immune System 0.99 >=0.20 0.43 >=0.20 0.64 >=0.20 
A14.549.167 Dentition Stomatognathic System Mouth 0.97 >=0.20 0.92 >=0.20 0.85 >=0.20 
A08.186.211.730.317 Diencephalon Nervous System Central Nervous 
System 
0.55 >=0.20 0.21 >=0.20 0.5 >=0.20 
A11.872.190.260 Embryoid Bodies Cells Stem Cells 0.87 >=0.20 0.99 >=0.20 0.98 >=0.20 
A11.872.190 Embryonic Stem Cells Cells Stem Cells 0.45 >=0.20 0.82 >=0.20 0.25 >=0.20 
A11.382 Endocrine Cells Cells Endocrine Cells 0.07 >=0.20 0.69 >=0.20 0.92 >=0.20 
A06.407 Endocrine Glands Endocrine System Endocrine Glands 0.05 >=0.20 0.38 >=0.20 0.24 >=0.20 
A05.360.319.679.490 Endometrium Urogenital System Genitalia 0.13 >=0.20 0.55 >=0.20 0.26 >=0.20 
A11.436.275 Endothelial Cells Cells Epithelial Cells 0.9 >=0.20 0.98 >=0.20 0.69 >=0.20 
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False discovery rate 
A11.436 Epithelial Cells Cells Epithelial Cells 0.86 >=0.20 1 >=0.20 0.77 >=0.20 
A10.272 Epithelium Tissues Epithelium 0.21 >=0.20 0.92 >=0.20 0.09 >=0.20 
A15.145.229.334 Erythrocytes Hemic and Immune 
Systems 
Blood 0.91 >=0.20 0.56 >=0.20 0.96 >=0.20 
A11.443 Erythroid Cells Cells Erythroid Cells 0.92 >=0.20 0.57 >=0.20 0.96 >=0.20 
A15.378.316.378.590.837.250 Erythroid Precursor Cells Hemic and Immune 
Systems 
Hematopoietic System 0.79 >=0.20 0.82 >=0.20 0.37 >=0.20 
A03.556.875.500 Esophagus Digestive System Gastrointestinal Tract 0.31 >=0.20 0.89 >=0.20 0.67 >=0.20 
A10.336 Exocrine Glands Tissues Exocrine Glands 0.11 >=0.20 0.97 >=0.20 0.58 >=0.20 
A10.615.284 Extraembryonic Membranes Tissues Membranes 0.64 >=0.20 0.97 >=0.20 0.93 >=0.20 
A09.371 Eye Sense Organs Eye 0.29 >=0.20 0.23 >=0.20 0.05 >=0.20 
A09.371.337 Eyelids Sense Organs Eye 0.76 >=0.20 0.98 >=0.20 0.36 >=0.20 
A05.360.319.114.373 Fallopian Tubes Urogenital System Genitalia 0.19 >=0.20 0.36 >=0.20 0.12 >=0.20 
A15.145.300 Fetal Blood Hemic and Immune 
Systems 
Blood 0.98 >=0.20 0.18 >=0.20 0.96 >=0.20 
A11.329.228 Fibroblasts Cells Connective Tissue Cells 0.27 >=0.20 0.94 >=0.20 0.83 >=0.20 
A02.835.232.043.300 Foot Bones Musculoskeletal System Skeleton 0.76 >=0.20 0.97 >=0.20 0.41 >=0.20 
A05.360.444.492.362 Foreskin Urogenital System Genitalia 0.35 >=0.20 1 >=0.20 0.75 >=0.20 
A08.186.211.730.885.287.500.27
0 
Frontal Lobe Nervous System Central Nervous 
System 
0.39 >=0.20 0.12 >=0.20 0.29 >=0.20 
A03.556 Gastrointestinal Tract Digestive System Gastrointestinal Tract 0.47 >=0.20 0.93 >=0.20 0.81 >=0.20 
A05.360 Genitalia Urogenital System Genitalia 0.08 >=0.20 0.82 >=0.20 0.37 >=0.20 
A05.360.319 Genitalia  Female Urogenital System Genitalia 0.13 >=0.20 0.45 >=0.20 0.24 >=0.20 
A05.360.444 Genitalia  Male Urogenital System Genitalia 0.1 >=0.20 0.98 >=0.20 0.57 >=0.20 
A05.360.490 Germ Cells Urogenital System Genitalia 0.32 >=0.20 0.99 >=0.20 0.91 >=0.20 
A11.436.294.064 Glucagon Secreting Cells Cells Epithelial Cells 0.28 >=0.20 0.95 >=0.20 0.39 >=0.20 
A06.407.312 Gonads Endocrine System Endocrine Glands 0.13 >=0.20 0.44 >=0.20 0.26 >=0.20 
A10.165.450 Granulation Tissue Tissues Connective Tissue 0.86 >=0.20 0.81 >=0.20 0.66 >=0.20 
A11.872.378.590.635 Granulocyte Macrophage Progenitor 
Cells 
Cells Stem Cells 1 >=0.20 0.76 >=0.20 0.99 >=0.20 
A11.627.340.360 Granulocyte Precursor Cells Cells Myeloid Cells 0.98 >=0.20 0.55 >=0.20 0.6 >=0.20 
A11.118.637.415 Granulocytes Cells Blood Cells 0.96 >=0.20 0.42 >=0.20 0.77 >=0.20 
A11.436.329 Granulosa Cells Cells Epithelial Cells 0.09 >=0.20 0.36 >=0.20 0.99 >=0.20 
A07.541 Heart Cardiovascular System Heart 0.77 >=0.20 0.55 >=0.20 0.78 >=0.20 
A07.541.358 Heart Atria Cardiovascular System Heart 0.35 >=0.20 0.16 >=0.20 0.65 >=0.20 
A07.541.510 Heart Valves Cardiovascular System Heart 0.14 >=0.20 0.35 >=0.20 0.11 >=0.20 
A07.541.560 Heart Ventricles Cardiovascular System Heart 0.83 >=0.20 0.6 >=0.20 0.83 >=0.20 
A11.872.378 Hematopoietic Stem Cells Cells Stem Cells 0.99 >=0.20 0.7 >=0.20 0.85 >=0.20 
A15.378 Hematopoietic System Hemic and Immune 
Systems 
Hematopoietic System 1 >=0.20 0.48 >=0.20 0.93 >=0.20 
A11.436.348 Hepatocytes Cells Epithelial Cells 0.48 >=0.20 0.87 >=0.20 0.82 >=0.20 
A08.186.211.730.317.357.352.43
5 
Hypothalamo Hypophyseal System Nervous System Central Nervous 
System 
0.27 >=0.20 0.17 >=0.20 0.54 >=0.20 
A08.186.211.730.317.357 Hypothalamus Nervous System Central Nervous 
System 
0.34 >=0.20 0.18 >=0.20 0.53 >=0.20 
A08.186.211.730.317.357.352 Hypothalamus  Middle Nervous System Central Nervous 
System 
0.27 >=0.20 0.17 >=0.20 0.54 >=0.20 
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False discovery rate 
A15.382 Immune System Hemic and Immune 
Systems 
Immune System 0.99 >=0.20 0.13 >=0.20 0.96 >=0.20 
A11.872.700.500 Induced Pluripotent Stem Cells Cells Stem Cells 0.41 >=0.20 0.83 >=0.20 0.35 >=0.20 
A03.556.124.369 Intestinal Mucosa Digestive System Gastrointestinal Tract 0.63 >=0.20 0.99 >=0.20 0.71 >=0.20 
A03.556.249.249 Intestine  Large Digestive System Gastrointestinal Tract 0.3 >=0.20 0.76 >=0.20 0.74 >=0.20 
A03.556.124.684 Intestine  Small Digestive System Gastrointestinal Tract 0.52 >=0.20 0.62 >=0.20 0.95 >=0.20 
A03.556.124 Intestines Digestive System Gastrointestinal Tract 0.37 >=0.20 0.86 >=0.20 0.76 >=0.20 
A03.734.414 Islets of Langerhans Digestive System Pancreas 0.32 >=0.20 0.97 >=0.20 0.47 >=0.20 
A02.835.583.443 Joint Capsule Musculoskeletal System Skeleton 0.38 >=0.20 0.65 >=0.20 0.98 >=0.20 
A02.835.583 Joints Musculoskeletal System Skeleton 0.38 >=0.20 0.65 >=0.20 0.98 >=0.20 
A10.165.450.300.425 Keloid Tissues Connective Tissue 0.89 >=0.20 0.86 >=0.20 0.53 >=0.20 
A11.436.397 Keratinocytes Cells Epithelial Cells 0.99 >=0.20 1 >=0.20 0.83 >=0.20 
A05.810.453 Kidney Urogenital System Urinary Tract 0.15 >=0.20 0.31 >=0.20 0.52 >=0.20 
A05.810.453.324 Kidney Cortex Urogenital System Urinary Tract 0.2 >=0.20 0.39 >=0.20 0.89 >=0.20 
A15.382.490.555.567.537 Killer Cells  Natural Hemic and Immune 
Systems 
Immune System 0.47 >=0.20 0.22 >=0.20 0.67 >=0.20 
A11.118.637 Leukocytes Cells Blood Cells 0.98 >=0.20 0.13 >=0.20 0.97 >=0.20 
A15.145.229.637.555 Leukocytes  Mononuclear Hemic and Immune 
Systems 
Blood 0.96 >=0.20 0.09 >=0.20 0.98 >=0.20 
A03.620 Liver Digestive System Liver 0.05 >=0.20 0.37 >=0.20 0.4 >=0.20 
A03.556.249 Lower Gastrointestinal Tract Digestive System Gastrointestinal Tract 0.3 >=0.20 0.76 >=0.20 0.75 >=0.20 
A04.411 Lung Respiratory System Lung 0.15 >=0.20 0.74 >=0.20 0.42 >=0.20 
A10.549.400 Lymph Nodes Tissues Lymphoid Tissue 0.84 >=0.20 0.04 >=0.20 0.8 >=0.20 
A15.382.520 Lymphatic System Hemic and Immune 
Systems 
Immune System 0.76 >=0.20 0.04 >=0.20 0.74 >=0.20 
A15.382.490.555.567 Lymphocytes Hemic and Immune 
Systems 
Immune System 0.76 >=0.20 0.04 >=0.20 0.95 >=0.20 
A15.382.490.555.567.622 Lymphocytes  Null Hemic and Immune 
Systems 
Immune System 0.91 >=0.20 0.58 >=0.20 0.49 >=0.20 
A11.872.378.294 Lymphoid Progenitor Cells Cells Stem Cells 0.29 >=0.20 0.06 >=0.20 0.23 >=0.20 
A10.549 Lymphoid Tissue Tissues Lymphoid Tissue 0.76 >=0.20 0.04 >=0.20 0.74 >=0.20 
A15.382.812.522 Macrophages Hemic and Immune 
Systems 
Immune System 1 >=0.20 0.88 >=0.20 0.66 >=0.20 
A11.329.372.600 Macrophages  Alveolar Cells Connective Tissue Cells 1 >=0.20 0.79 >=0.20 0.13 >=0.20 
A11.872.378.590.817 Megakaryocyte Erythroid Progenitor 
Cells 
Cells Stem Cells 0.79 >=0.20 0.82 >=0.20 0.37 >=0.20 
A10.615 Membranes Tissues Membranes 0.45 >=0.20 1 >=0.20 0.54 >=0.20 
A08.186.211.653 Mesencephalon Nervous System Central Nervous 
System 
0.49 >=0.20 0.32 >=0.20 0.26 >=0.20 
A11.872.580 Mesenchymal Stem Cells Cells Stem Cells 0.37 >=0.20 0.78 >=0.20 0.87 >=0.20 
A11.627.624.249 Monocyte Macrophage Precursor Cells Cells Myeloid Cells 1 >=0.20 0.78 >=0.20 1 >=0.20 
A15.378.316.580 Monocytes Hemic and Immune 
Systems 
Hematopoietic System 1 >=0.20 0.55 >=0.20 0.97 >=0.20 
A15.382.812 Mononuclear Phagocyte System Hemic and Immune 
Systems 
Immune System 1 >=0.20 0.62 >=0.20 0.84 >=0.20 
A14.549 Mouth Stomatognathic System Mouth 0.8 >=0.20 0.99 >=0.20 0.81 >=0.20 
A10.615.550.599 Mouth Mucosa Tissues Membranes 0.46 >=0.20 0.96 >=0.20 0.38 >=0.20 
A10.615.550 Mucous Membrane Tissues Membranes 0.47 >=0.20 0.99 >=0.20 0.4 >=0.20 
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A10.690.467 Muscle  Smooth Tissues Muscles 0.99 >=0.20 0.99 >=0.20 0.95 >=0.20 
A10.690.552 Muscle  Striated Tissues Muscles 0.84 >=0.20 0.27 >=0.20 0.92 >=0.20 
A11.620 Muscle Cells Cells Muscle Cells 1 >=0.20 1 >=0.20 0.99 >=0.20 
A10.690 Muscles Tissues Muscles 0.93 >=0.20 0.49 >=0.20 0.96 >=0.20 
A11.627 Myeloid Cells Cells Myeloid Cells 1 >=0.20 0.61 >=0.20 0.87 >=0.20 
A11.627.635 Myeloid Progenitor Cells Cells Myeloid Cells 0.99 >=0.20 0.82 >=0.20 0.92 >=0.20 
A11.620.520 Myocytes  Smooth Muscle Cells Muscle Cells 1 >=0.20 1 >=0.20 0.99 >=0.20 
A05.360.319.679.690 Myometrium Urogenital System Genitalia 0.04 >=0.20 0.26 >=0.20 0.16 >=0.20 
A04.531.520 Nasal Mucosa Respiratory System Nose 0.22 >=0.20 0.84 >=0.20 0.23 >=0.20 
A14.724.557 Nasopharynx Stomatognathic System Pharynx 1 >=0.20 0.8 >=0.20 0.51 >=0.20 
A08.713 Neurosecretory Systems Nervous System Neurosecretory 
Systems 
0.27 >=0.20 0.17 >=0.20 0.54 >=0.20 
A15.382.490.315.583 Neutrophils Hemic and Immune 
Systems 
Immune System 0.95 >=0.20 0.41 >=0.20 0.76 >=0.20 
A09.531 Nose Sense Organs Nose 0.22 >=0.20 0.84 >=0.20 0.23 >=0.20 
A11.497.497.600 Oocytes Cells Germ Cells 0.12 >=0.20 0.95 >=0.20 0.75 >=0.20 
A04.623.603 Oropharynx Respiratory System Pharynx 0.75 >=0.20 0.1 >=0.20 0.61 >=0.20 
A11.329.629 Osteoblasts Cells Connective Tissue Cells 0.54 >=0.20 0.63 >=0.20 0.55 >=0.20 
A05.360.319.114.630.535 Ovarian Follicle Urogenital System Genitalia 0.09 >=0.20 0.36 >=0.20 0.99 >=0.20 
A05.360.319.114.630 Ovary Urogenital System Genitalia 0.14 >=0.20 0.37 >=0.20 0.24 >=0.20 
A05.360.490.690 Ovum Urogenital System Genitalia 0.12 >=0.20 0.95 >=0.20 0.75 >=0.20 
A15.382.520.604.800 Palatine Tonsil Hemic and Immune 
Systems 
Immune System 0.75 >=0.20 0.1 >=0.20 0.61 >=0.20 
A03.734 Pancreas Digestive System Pancreas 0.19 >=0.20 0.75 >=0.20 0.28 >=0.20 
A08.186.211.730.885.287.500.67
0 
Parietal Lobe Nervous System Central Nervous 
System 
0.08 >=0.20 9.67E-03 >=0.20 0.12 >=0.20 
A03.556.500.760.464 Parotid Gland Digestive System Gastrointestinal Tract 0.52 >=0.20 0.73 >=0.20 0.97 >=0.20 
A05.360.444.492 Penis Urogenital System Genitalia 0.34 >=0.20 1 >=0.20 0.75 >=0.20 
A14.549.167.646 Periodontium Stomatognathic System Mouth 0.92 >=0.20 0.89 >=0.20 0.8 >=0.20 
A15.382.680 Phagocytes Hemic and Immune 
Systems 
Immune System 1 >=0.20 0.59 >=0.20 0.87 >=0.20 
A14.724 Pharynx Stomatognathic System Pharynx 1 >=0.20 0.54 >=0.20 0.57 >=0.20 
A15.145.693 Plasma Hemic and Immune 
Systems 
Blood 0.87 >=0.20 0.15 >=0.20 0.99 >=0.20 
A15.145.229.637.555.567.562.72
5 
Plasma Cells Hemic and Immune 
Systems 
Blood 0.87 >=0.20 0.16 >=0.20 0.99 >=0.20 
A11.872.700 Pluripotent Stem Cells Cells Stem Cells 0.41 >=0.20 0.83 >=0.20 0.35 >=0.20 
A07.231.908.670 Portal System Cardiovascular System Blood Vessels 0.89 >=0.20 0.95 >=0.20 0.53 >=0.20 
A11.118.637.555.567.562.440 Precursor Cells  B Lymphoid Cells Blood Cells 0.29 >=0.20 0.06 >=0.20 0.23 >=0.20 
A10.336.707 Prostate Tissues Exocrine Glands 0.11 >=0.20 0.96 >=0.20 0.53 >=0.20 
A02.633.567.850 Quadriceps Muscle Musculoskeletal System Muscles 0.85 >=0.20 0.26 >=0.20 0.93 >=0.20 
A03.556.124.526.767 Rectum Digestive System Gastrointestinal Tract 0.58 >=0.20 0.51 >=0.20 0.98 >=0.20 
A10.615.550.760 Respiratory Mucosa Tissues Membranes 0.22 >=0.20 0.84 >=0.20 0.23 >=0.20 
A03.556.500.760 Salivary Glands Digestive System Gastrointestinal Tract 0.6 >=0.20 0.73 >=0.20 0.98 >=0.20 
A10.615.789 Serous Membrane Tissues Membranes 0.39 >=0.20 0.69 >=0.20 0.61 >=0.20 
A15.145.846 Serum Hemic and Immune 
Systems 
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A02.835 Skeleton Musculoskeletal System Skeleton 0.98 >=0.20 0.21 >=0.20 0.96 >=0.20 
A17.815 Skin Integumentary System Skin 0.28 >=0.20 0.99 >=0.20 0.25 >=0.20 
A02.835.232.834 Spine Musculoskeletal System Skeleton 0.36 >=0.20 0.75 >=0.20 0.48 >=0.20 
A15.382.520.604.700 Spleen Hemic and Immune 
Systems 
Immune System 0.1 >=0.20 0.19 >=0.20 0.4 >=0.20 
A11.872 Stem Cells Cells Stem Cells 0.81 >=0.20 0.79 >=0.20 0.66 >=0.20 
A03.556.875.875 Stomach Digestive System Gastrointestinal Tract 0.35 >=0.20 0.64 >=0.20 0.71 >=0.20 
A11.329.830 Stromal Cells Cells Connective Tissue Cells 0.49 >=0.20 0.94 >=0.20 0.87 >=0.20 
A10.165.114.830.750 Subcutaneous Fat Tissues Connective Tissue 0.6 >=0.20 0.55 >=0.20 0.23 >=0.20 
A10.165.114.830.500.750 Subcutaneous Fat  Abdominal Tissues Connective Tissue 0.68 >=0.20 0.56 >=0.20 0.26 >=0.20 
A02.835.583.443.800.800 Synovial Fluid Musculoskeletal System Skeleton 0.72 >=0.20 0.2 >=0.20 0.84 >=0.20 
A02.835.583.443.800 Synovial Membrane Musculoskeletal System Skeleton 0.38 >=0.20 0.65 >=0.20 0.98 >=0.20 
A11.118.637.555.567.569 T Lymphocytes Cells Blood Cells 0.6 >=0.20 0.08 >=0.20 0.68 >=0.20 
A11.118.637.555.567.569.200.70
0 
T Lymphocytes  Regulatory Cells Blood Cells 0.23 >=0.20 0.1 >=0.20 0.24 >=0.20 
A02.835.232.043.300.710 Tarsal Bones Musculoskeletal System Skeleton 0.76 >=0.20 0.97 >=0.20 0.41 >=0.20 
A06.407.312.782 Testis Endocrine System Endocrine Glands 0.31 >=0.20 0.93 >=0.20 0.57 >=0.20 
A06.407.900 Thyroid Gland Endocrine System Endocrine Glands 0.16 >=0.20 0.23 >=0.20 0.41 >=0.20 
A14.549.885 Tongue Stomatognathic System Mouth 0.98 >=0.20 0.99 >=0.20 0.98 >=0.20 
A07.231.908.670.874 Umbilical Veins Cardiovascular System Blood Vessels 0.89 >=0.20 0.95 >=0.20 0.53 >=0.20 
A03.556.875 Upper Gastrointestinal Tract Digestive System Gastrointestinal Tract 0.39 >=0.20 0.75 >=0.20 0.77 >=0.20 
A05.810.890 Urinary Bladder Urogenital System Urinary Tract 0.65 >=0.20 0.47 >=0.20 0.83 >=0.20 
A05.810 Urinary Tract Urogenital System Urinary Tract 0.16 >=0.20 0.32 >=0.20 0.54 >=0.20 
A05.360.319.679 Uterus Urogenital System Genitalia 0.16 >=0.20 0.53 >=0.20 0.37 >=0.20 
A07.231.908 Veins Cardiovascular System Blood Vessels 0.92 >=0.20 0.95 >=0.20 0.65 >=0.20 










Table S19. Functional eQTL genes associated with caffeine intake 
GWAS SNP Caffeine 
Trait 
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GTEx - Cells Transformed 
fibroblasts 
eQTL gene mapping was performed using a SMR approach in data repositories from GTEx V7, GTEx brain, Brain-eMeta eQTL and blood eQTL (Westra and CAGE). eQTL genes were considered candidate causal genes if they passed the SMR test with Bonferroni-corrected P value <2.7x10-7, passed the HEIDI test with 
P>0.05, and if the lead SNP of the eQTL gene was in LD (R2>0.8) with the queried caffeine intake SNPs. Abbreviations: SNP, single nucleotide polymorphism; CHR, chromosome; EFAL, effect allele; NEFAL, non-effect allele; EF Freq, effect allele frequency; SE, standard error; eQTL, expression quantitative trait locus; 









Table S20. SNPs and proxies for Mendelian Randomization analyses for combined caffeine intake on coronary artery disease 
SNP CHR BP ALLELE1 ALLELE0 A1FREQ BETA SE P value Proxy for R2 
rs7412396 1 150666797 G A 0.597491 -0.02279 0.002364 5.50E-22 rs768283768 0.930744 
rs2987869 1 174789407 G T 0.458638 -0.01562 0.002332 2.10E-11 1:174856749_TG_T 0.998626 
rs1260326 2 27730940 T C 0.391852 -0.02297 0.002377 4.20E-22 
  
rs78456557 3 123300686 C G 0.900201 -0.02364 0.00389 1.20E-09 
  
rs114066728 3 142022265 T C 0.870043 -0.02127 0.003456 7.50E-10 rs115454798 0.991139 
rs2231142 4 89052323 G T 0.886707 0.03913 0.00366 1.10E-26 
  
rs62332762 4 106143492 C T 0.597585 0.01828 0.002368 1.20E-14 
  
rs12514566 5 7391462 G A 0.664698 0.017242 0.002456 2.20E-12 
  
rs1872841 6 98576688 C A 0.483724 -0.01316 0.002328 1.60E-08 rs754177720 0.902704 
rs9486902 6 108878052 C T 0.837869 0.018849 0.00315 2.20E-09 6:108876096_CAAT_C 0.997488 
rs1490384 6 126851160 C T 0.501467 -0.01587 0.002323 8.30E-12 
  
rs139797380 6 137244957 C G 0.991601 0.106741 0.013575 3.70E-15 
  
rs4410790 7 17284577 T C 0.364122 -0.08137 0.002412 1.50E-249 
  
rs215601 7 32333921 A C 0.372618 0.01488 0.002404 6.00E-10 
  
rs34060476 7 73037956 A G 0.865587 -0.03535 0.003404 2.90E-25 7:73042302_GCTTT_G 0.99198 
rs17685 7 75616105 G A 0.721471 -0.0408 0.002584 3.80E-56 
  
rs4240624 8 9184231 G A 0.092461 0.02693 0.004012 1.90E-11 
  
rs12785227 10 65262685 A G 0.685798 0.014549 0.002507 6.50E-09 
  
rs4418728 10 94839724 G T 0.550788 0.014384 0.002333 7.00E-10 
  
rs117810762 10 135315795 G A 0.982023 -0.06827 0.008863 1.30E-14 
  
rs6265 11 27679916 C T 0.810755 0.021572 0.002964 3.40E-13 
  
rs1228024 11 47951353 C A 0.340021 0.013965 0.002453 1.30E-08 
  
rs7105462 11 112912048 G A 0.40559 0.014163 0.002366 2.10E-09 
  
rs595529 12 112000648 A T 0.796265 -0.01662 0.002882 8.10E-09 rs376877108 0.993627 
rs12591786 15 60902512 C T 0.842038 0.020213 0.00323 3.90E-10 
  
rs2472297 15 75027880 C T 0.731645 -0.10487 0.002616 2.4E-351 
  
rs2667773 15 77872191 A G 0.686772 0.014947 0.002506 2.50E-09 
  
rs59681738 16 18788186 A G 0.618174 0.013733 0.002417 1.30E-08 16:18776851_G_GA 0.934833 
rs489693 18 57882787 C A 0.67465 -0.01759 0.002478 1.30E-12 
  
rs56113850 19 41353107 T C 0.421755 -0.02649 0.002351 1.90E-29 
  
rs138761767 19 47559089 T C 0.25755 -0.01627 0.002695 1.60E-09 rs61141867 0.90578 
rs1291145 20 35528475 T C 0.313259 -0.01456 0.002506 6.30E-09 20:35568001_AAAAG_A 0.998402 
rs6062679 20 62889991 T C 0.534615 -0.02278 0.002358 4.50E-22 
  
rs190800998 22 24666292 T C 0.985779 0.090577 0.009889 5.20E-20 rs199612805 1 
rs9611527 22 41644428 G A 0.664286 0.019792 0.002466 1.00E-15 
  
Sentinel single nucleotide polymorphisms (SNPs) and proxies used are provided for the Mendelian randomization analyses. In case a proxy was used, the original sentinel SNP is provided in the "Proxy for" column and the R2 between them in the "R2" column. No proxy with R2>0.8 was available for 









Table S21. SNPs and proxies for Mendelian Randomization analyses for caffeine from coffee on coronary artery disease 
SNP CHR BP ALLELE1 ALLELE0 A1FREQ BETA SE P value Proxy for R2 
rs4615895 1 96274668 G A 0.259574 -0.01705 0.002627 8.60E-11 
  
rs7412396 1 150666797 G A 0.597371 -0.01297 0.002337 2.90E-08 rs768283768 0.930744 
rs7571957 2 646803 T C 0.170688 -0.02056 0.003047 1.50E-11 rs7571970 0.99315 
rs11127048 2 27752463 G A 0.381191 -0.01997 0.002398 8.10E-17 
  
rs35198275 3 50536092 A G 0.865693 0.020797 0.003387 8.20E-10 
  
rs2726513 4 106217358 G T 0.587077 0.015301 0.002347 7.00E-11 
  
rs12514566 5 7391462 G A 0.664625 0.014831 0.002428 1.00E-09 
  
rs6893807 5 87965021 A G 0.843563 -0.01916 0.003159 1.30E-09 
  
rs1327259 6 51177811 A G 0.614152 0.015707 0.002365 3.10E-11 
  
rs4410790 7 17284577 T C 0.364412 -0.05171 0.002384 2.80E-104 
  
rs34060476 7 73037956 A G 0.865581 -0.02519 0.003365 7.10E-14 
  
rs1057868 7 75615006 C T 0.714413 -0.02445 0.002536 5.50E-22 
  
rs76881016 10 134196286 A G 0.928496 -0.02584 0.004453 6.60E-09 
  
rs117810762 10 135315795 G A 0.982047 -0.05011 0.008765 1.10E-08 
  
rs2298527 11 112851961 G C 0.405568 0.014947 0.002336 1.60E-10 
  
rs2472297 15 75027880 C T 0.731859 -0.06521 0.002587 3.10E-140 
  
rs2521501 15 91437388 A T 0.677316 0.014916 0.002472 1.60E-09 
  
rs28567725 16 53826028 T C 0.5877 -0.02172 0.002331 1.20E-20 rs201399553 0.945928 
rs2350633 17 17587395 A G 0.486877 -0.01469 0.002296 1.60E-10 rs139937261 0.997277 
rs66723169 18 57808978 C A 0.769043 -0.02249 0.002732 1.80E-16 
  
rs56113850 19 41353107 T C 0.421821 -0.02071 0.002323 4.90E-19 
  
rs6063085 20 45840459 A C 0.625251 -0.01571 0.00237 3.40E-11 
  
rs181251778 22 24901968 A G 0.986146 0.072648 0.009834 1.50E-13 
  
Sentinel single nucleotide polymorphisms (SNPs) and proxies used are provided for the Mendelian randomization analyses. In case a proxy was used, the original sentinel SNP is provided in the "Proxy for" column and the R2 between them in the "R2" column. No proxy with R2>0.8 was available for rs1962201, which was 









Table S22. SNPs and proxies for Mendelian Randomization analyses for caffeine from tea on coronary artery disease 
SNP CHR BP ALLELE1 ALLELE0 A1FREQ BETA SE P value Proxy for R2 
rs9438624 1 26758044 C T 0.19273 -0.01535 0.002844 6.70E-08 rs77476394 0.887444 
rs11204708 1 150682095 C G 0.619872 -0.01428 0.002349 1.20E-09 rs11204711 0.998421 
rs56188862 1 174189269 T C 0.614947 0.016829 0.002297 2.40E-13 
  
rs78020607 3 50254624 A G 0.887096 -0.01866 0.003527 1.20E-07 rs145755097 0.869438 
rs2117137 3 89525505 A G 0.594554 -0.01349 0.002273 2.90E-09 
  
rs1481012 4 89039082 A G 0.887297 0.026005 0.003536 1.90E-13 
  
rs192084998 5 152077481 G A 0.703764 0.015836 0.002458 1.20E-10 
  
rs2465018 6 51241140 G A 0.769413 -0.02211 0.002666 1.10E-16 
  
rs139797380 6 137244957 C G 0.991607 0.075145 0.013059 8.70E-09 
  
rs4410790 7 17284577 T C 0.36537 -0.04033 0.00232 1.10E-67 
  
rs6462899 7 39296489 T A 0.375354 -0.01259 0.002312 5.10E-08 rs141180025 0.943469 
rs17685 7 75616105 G A 0.721688 -0.02391 0.002488 7.20E-22 
  
rs62534435 9 7042938 C G 0.796528 -0.01629 0.002776 4.40E-09 
  
rs11022752 11 13307622 A G 0.730907 -0.01535 0.002525 1.20E-09 
  
rs10741694 11 16286183 T C 0.372823 -0.01474 0.002312 1.80E-10 
  
rs73053413 12 11329548 C T 0.836535 0.021681 0.003021 7.10E-13 
  
rs12591786 15 60902512 C T 0.842256 0.019576 0.003109 3.00E-10 
  
rs2472297 15 75027880 C T 0.732806 -0.05411 0.002521 3.30E-102 
  
rs28429148 16 53798319 G A 0.565413 0.013189 0.002288 8.20E-09 
  
rs153328 16 63025865 C G 0.782673 -0.01445 0.002718 1.10E-07 rs199602679 0.976937 
rs140775622 20 62962869 C T 0.830545 -0.02262 0.003207 1.80E-12 
  
rs4817505 21 34343828 T C 0.607874 -0.01512 0.002292 4.20E-11 
  
rs9624470 22 24820268 G A 0.419254 -0.02534 0.002272 6.80E-29 
  
rs132919 22 41809903 G C 0.22639 -0.01708 0.002697 2.40E-10 
  









Table S23. F-statistics of all instruments for the Mendelian Randomization analyses between caffeine intake and CAD or T2D 
GWAS trait SNP CHR hg19 EFAL NEFAL EF Freq BETA SE R2 N F Statistic P STATA P GWAS MR 
Combined caffeine intake rs7412396 1 150666797 G A 0.597491 -0.02279 0.002364 0.014067 362316 5169.384 1.73E-21 5.50E-22 CAD 
Combined caffeine intake rs2987869 1 174789407 G T 0.458638 -0.01562 0.002332 0.013936 362316 5120.384 3.91E-11 2.10E-11 CAD 
Combined caffeine intake rs1260326 2 27730940 T C 0.391852 -0.02297 0.002377 0.014068 362316 5169.591 8.45E-22 4.20E-22 CAD 
Combined caffeine intake rs78456557 3 123300686 C G 0.900201 -0.02364 0.00389 0.013912 362316 5111.729 3.18E-09 1.20E-09 CAD 
Combined caffeine intake rs114066728 3 142022265 T C 0.870043 -0.02127 0.003456 0.013924 362316 5115.983 4.60E-10 7.50E-10 CAD 
Combined caffeine intake rs2231142 4 89052323 G T 0.886707 0.03913 0.00366 0.014118 362316 5188.382 4.78E-26 1.10E-26 CAD 
Combined caffeine intake rs62332762 4 106143492 C T 0.597585 0.01828 0.002368 0.013985 362316 5138.959 6.20E-15 1.20E-14 CAD 
Combined caffeine intake rs12514566 5 7391462 G A 0.664698 0.017242 0.002456 0.013963 362316 5130.563 2.59E-13 2.20E-12 CAD 
Combined caffeine intake rs1872841 6 98576688 C A 0.483724 -0.01316 0.002328 0.013899 362316 5106.653 4.52E-08 1.60E-08 CAD 
Combined caffeine intake rs9486902 6 108878052 C T 0.837869 0.018849 0.00315 0.013912 362316 5111.45 4.20E-09 2.20E-09 CAD 
Combined caffeine intake rs1490384 6 126851160 C T 0.501467 -0.01587 0.002323 0.013936 362316 5120.626 3.76E-11 8.30E-12 CAD 
Combined caffeine intake rs139797380 6 137244957 C G 0.991601 0.106741 0.013575 0.013989 362316 5140.392 5.51E-16 3.70E-15 CAD 
Combined caffeine intake rs4410790 7 17284577 T C 0.364122 -0.08137 0.002412 0.016873 362316 6218.187 4.90E-248 1.50E-249 CAD 
Combined caffeine intake rs215601 7 32333921 A C 0.372618 0.01488 0.002404 0.013919 362316 5114.316 9.96E-10 6.00E-10 CAD 
Combined caffeine intake rs34060476 7 73037956 A G 0.865587 -0.03535 0.003404 0.014101 362316 5182.065 7.21E-24 2.90E-25 CAD 
Combined caffeine intake rs17685 7 75616105 G A 0.721471 -0.0408 0.002584 0.014481 362316 5323.936 2.32E-54 3.80E-56 CAD 
Combined caffeine intake rs4240624 8 9184231 G A 0.092461 0.02693 0.004012 0.01394 362316 5122.161 2.03E-11 1.90E-11 CAD 
Combined caffeine intake rs12785227 10 65262685 A G 0.685798 0.014549 0.002507 0.0139 362316 5107.326 3.26E-08 6.50E-09 CAD 
Combined caffeine intake rs4418728 10 94839724 G T 0.550788 0.014384 0.002333 0.013924 362316 5116.012 3.88E-10 7.00E-10 CAD 
Combined caffeine intake rs117810762 10 135315795 G A 0.982023 -0.06827 0.008863 0.013972 362316 5134.15 4.37E-14 1.30E-14 CAD 
Combined caffeine intake rs6265 11 27679916 C T 0.810755 0.021572 0.002964 0.013957 362316 5128.536 7.83E-13 3.40E-13 CAD 
Combined caffeine intake rs1228024 11 47951353 C A 0.340021 0.013965 0.002453 0.013901 362316 5107.388 3.28E-08 1.30E-08 CAD 
Combined caffeine intake rs7105462 11 112912048 G A 0.40559 0.014163 0.002366 0.013919 362316 5114.38 9.50E-10 2.10E-09 CAD 
Combined caffeine intake rs595529 12 112000648 A T 0.796265 -0.01662 0.002882 0.013909 362316 5110.631 5.94E-09 8.10E-09 CAD 
Combined caffeine intake rs12591786 15 60902512 C T 0.842038 0.020213 0.00323 0.013914 362316 5112.39 2.27E-09 3.90E-10 CAD 
Combined caffeine intake rs2472297 15 75027880 C T 0.731645 -0.10487 0.002616 0.01816 362316 6701.501 0 2.4E-351 CAD 
Combined caffeine intake rs2667773 15 77872191 A G 0.686772 0.014947 0.002506 0.013912 362316 5111.556 3.88E-09 2.50E-09 CAD 
Combined caffeine intake rs59681738 16 18788186 A G 0.618174 0.013733 0.002417 0.013904 362316 5108.777 1.57E-08 1.30E-08 CAD 
Combined caffeine intake rs489693 18 57882787 C A 0.67465 -0.01759 0.002478 0.013947 362316 5124.483 6.86E-12 1.30E-12 CAD 
Combined caffeine intake rs56113850 19 41353107 T C 0.421755 -0.02649 0.002351 0.01416 362316 5203.96 3.48E-29 1.90E-29 CAD 
Combined caffeine intake rs138761767 19 47559089 T C 0.25755 -0.01627 0.002695 0.013915 362316 5112.586 2.17E-09 1.60E-09 CAD 
Combined caffeine intake rs1291145 20 35528475 T C 0.313259 -0.01456 0.002506 0.013905 362316 5108.846 1.53E-08 6.30E-09 CAD 
Combined caffeine intake rs6062679 20 62889991 T C 0.534615 -0.02278 0.002358 0.014074 362316 5172.107 3.00E-22 4.50E-22 CAD 
Combined caffeine intake rs190800998 22 24666292 T C 0.985779 0.090577 0.009889 0.014057 362316 5165.523 3.22E-20 5.20E-20 CAD 
Combined caffeine intake rs9611527 22 41644428 G A 0.664286 0.019792 0.002466 0.013997 362316 5143.193 6.20E-16 1.00E-15 CAD 
Combined caffeine intake rs7412396 1 150666797 G A 0.597491 -0.02279 0.002364 0.014067 362316 5169.384 1.73E-21 5.50E-22 T2D 
Combined caffeine intake rs2987869 1 174789407 G T 0.458638 -0.01562 0.002332 0.013936 362316 5120.384 3.91E-11 2.10E-11 T2D 
Combined caffeine intake rs1260326 2 27730940 T C 0.391852 -0.02297 0.002377 0.014068 362316 5169.591 8.45E-22 4.20E-22 T2D 
Combined caffeine intake rs78456557 3 123300686 C G 0.900201 -0.02364 0.00389 0.013912 362316 5111.729 3.18E-09 1.20E-09 T2D 
Combined caffeine intake rs114066728 3 142022265 T C 0.870043 -0.02127 0.003456 0.013924 362316 5115.983 4.60E-10 7.50E-10 T2D 
Combined caffeine intake rs2231142 4 89052323 G T 0.886707 0.03913 0.00366 0.014118 362316 5188.382 4.78E-26 1.10E-26 T2D 
Combined caffeine intake rs62332762 4 106143492 C T 0.597585 0.01828 0.002368 0.013985 362316 5138.959 6.20E-15 1.20E-14 T2D 
Combined caffeine intake rs12514566 5 7391462 G A 0.664698 0.017242 0.002456 0.013963 362316 5130.563 2.59E-13 2.20E-12 T2D 








GWAS trait SNP CHR hg19 EFAL NEFAL EF Freq BETA SE R2 N F Statistic P STATA P GWAS MR 
Combined caffeine intake rs9486902 6 108878052 C T 0.837869 0.018849 0.00315 0.013912 362316 5111.45 4.20E-09 2.20E-09 T2D 
Combined caffeine intake rs1490384 6 126851160 C T 0.501467 -0.01587 0.002323 0.013936 362316 5120.626 3.76E-11 8.30E-12 T2D 
Combined caffeine intake rs139797380 6 137244957 C G 0.991601 0.106741 0.013575 0.013989 362316 5140.392 5.51E-16 3.70E-15 T2D 
Combined caffeine intake rs4410790 7 17284577 T C 0.364122 -0.08137 0.002412 0.016873 362316 6218.187 4.90E-248 1.50E-249 T2D 
Combined caffeine intake rs215601 7 32333921 A C 0.372618 0.01488 0.002404 0.013919 362316 5114.316 9.96E-10 6.00E-10 T2D 
Combined caffeine intake rs34060476 7 73037956 A G 0.865587 -0.03535 0.003404 0.014101 362316 5182.065 7.21E-24 2.90E-25 T2D 
Combined caffeine intake rs17685 7 75616105 G A 0.721471 -0.0408 0.002584 0.014481 362316 5323.936 2.32E-54 3.80E-56 T2D 
Combined caffeine intake rs4240624 8 9184231 G A 0.092461 0.02693 0.004012 0.01394 362316 5122.161 2.03E-11 1.90E-11 T2D 
Combined caffeine intake rs12785227 10 65262685 A G 0.685798 0.014549 0.002507 0.0139 362316 5107.326 3.26E-08 6.50E-09 T2D 
Combined caffeine intake rs4418728 10 94839724 G T 0.550788 0.014384 0.002333 0.013924 362316 5116.012 3.88E-10 7.00E-10 T2D 
Combined caffeine intake rs117810762 10 135315795 G A 0.982023 -0.06827 0.008863 0.013972 362316 5134.15 4.37E-14 1.30E-14 T2D 
Combined caffeine intake rs6265 11 27679916 C T 0.810755 0.021572 0.002964 0.013957 362316 5128.536 7.83E-13 3.40E-13 T2D 
Combined caffeine intake rs1228024 11 47951353 C A 0.340021 0.013965 0.002453 0.013901 362316 5107.388 3.28E-08 1.30E-08 T2D 
Combined caffeine intake rs7105462 11 112912048 G A 0.40559 0.014163 0.002366 0.013919 362316 5114.38 9.50E-10 2.10E-09 T2D 
Combined caffeine intake rs607316 12 111969448 C T 0.795666 -0.01678 0.002878 0.013911 362316 5111.429 3.96E-09 5.50E-09 T2D 
Combined caffeine intake rs12591786 15 60902512 C T 0.842038 0.020213 0.00323 0.013914 362316 5112.39 2.27E-09 3.90E-10 T2D 
Combined caffeine intake rs2472297 15 75027880 C T 0.731645 -0.10487 0.002616 0.01816 362316 6701.501 0 2.4E-351 T2D 
Combined caffeine intake rs2667773 15 77872191 A G 0.686772 0.014947 0.002506 0.013912 362316 5111.556 3.88E-09 2.50E-09 T2D 
Combined caffeine intake rs3965574 16 18789966 A G 0.61805 0.013716 0.002416 0.013904 362316 5108.739 1.60E-08 1.40E-08 T2D 
Combined caffeine intake rs489693 18 57882787 C A 0.67465 -0.01759 0.002478 0.013947 362316 5124.483 6.86E-12 1.30E-12 T2D 
Combined caffeine intake rs56113850 19 41353107 T C 0.421755 -0.02649 0.002351 0.01416 362316 5203.96 3.48E-29 1.90E-29 T2D 
Combined caffeine intake rs61599759 19 47557472 A G 0.245811 -0.01741 0.002732 0.013926 362316 5116.85 2.45E-10 1.80E-10 T2D 
Combined caffeine intake rs1291145 20 35528475 T C 0.313259 -0.01456 0.002506 0.013905 362316 5108.846 1.53E-08 6.30E-09 T2D 
Combined caffeine intake rs6062679 20 62889991 T C 0.534615 -0.02278 0.002358 0.014074 362316 5172.107 3.00E-22 4.50E-22 T2D 
Combined caffeine intake rs138019862 22 24821154 G T 0.986106 0.093407 0.009925 0.014071 362316 5171.046 2.18E-21 4.90E-21 T2D 
Combined caffeine intake rs9611527 22 41644428 G A 0.664286 0.019792 0.002466 0.013997 362316 5143.193 6.20E-16 1.00E-15 T2D 
Caffeine from coffee rs4615895 1 96274668 G A 0.259574 -0.01705 0.002627 0.011992 373522 4533.705 1.92E-10 8.60E-11 CAD 
Caffeine from coffee rs7412396 1 150666797 G A 0.597371 -0.01297 0.002337 0.01197 373522 4525.166 1.35E-08 2.90E-08 CAD 
Caffeine from coffee rs7571957 2 646803 T C 0.170688 -0.02056 0.003047 0.01201 373522 4540.678 4.81E-12 1.50E-11 CAD 
Caffeine from coffee rs11127048 2 27752463 G A 0.381191 -0.01997 0.002398 0.012081 373522 4567.802 6.74E-18 8.10E-17 CAD 
Caffeine from coffee rs35198275 3 50536092 A G 0.865693 0.020797 0.003387 0.011987 373522 4531.599 4.48E-10 8.20E-10 CAD 
Caffeine from coffee rs2726513 4 106217358 G T 0.587077 0.015301 0.002347 0.011987 373522 4531.666 5.18E-10 7.00E-11 CAD 
Caffeine from coffee rs12514566 5 7391462 G A 0.664625 0.014831 0.002428 0.011991 373522 4533.052 2.31E-10 1.00E-09 CAD 
Caffeine from coffee rs6893807 5 87965021 A G 0.843563 -0.01916 0.003159 0.011983 373522 4530.283 9.38E-10 1.30E-09 CAD 
Caffeine from coffee rs1327259 6 51177811 A G 0.614152 0.015707 0.002365 0.011995 373522 4534.635 1.14E-10 3.10E-11 CAD 
Caffeine from coffee rs4410790 7 17284577 T C 0.364412 -0.05171 0.002384 0.013193 373522 4993.793 6.01E-110 2.80E-104 CAD 
Caffeine from coffee rs34060476 7 73037956 A G 0.865581 -0.02519 0.003365 0.012032 373522 4549.021 1.47E-13 7.10E-14 CAD 
Caffeine from coffee rs1057868 7 75615006 C T 0.714413 -0.02445 0.002536 0.012128 373522 4585.517 9.77E-22 5.50E-22 CAD 
Caffeine from coffee rs76881016 10 134196286 A G 0.928496 -0.02584 0.004453 0.011957 373522 4520.214 1.39E-07 6.60E-09 CAD 
Caffeine from coffee rs117810762 10 135315795 G A 0.982047 -0.05011 0.008765 0.011989 373522 4532.505 3.50E-10 1.10E-08 CAD 
Caffeine from coffee rs2298527 11 112851961 G C 0.405568 0.014947 0.002336 0.011978 373522 4528.319 2.77E-09 1.60E-10 CAD 
Caffeine from coffee rs2472297 15 75027880 C T 0.731859 -0.06521 0.002587 0.013586 373522 5144.517 1.83E-138 3.10E-140 CAD 
Caffeine from coffee rs2521501 15 91437388 A T 0.677316 0.014916 0.002472 0.011971 373522 4525.774 1.02E-08 1.60E-09 CAD 
Caffeine from coffee rs28567725 16 53826028 T C 0.5877 -0.02172 0.002331 0.012113 373522 4579.932 1.89E-20 1.20E-20 CAD 








GWAS trait SNP CHR hg19 EFAL NEFAL EF Freq BETA SE R2 N F Statistic P STATA P GWAS MR 
Caffeine from coffee rs66723169 18 57808978 C A 0.769043 -0.02249 0.002732 0.012045 373522 4553.886 1.26E-14 1.80E-16 CAD 
Caffeine from coffee rs56113850 19 41353107 T C 0.421821 -0.02071 0.002323 0.012076 373522 4565.758 1.95E-17 4.90E-19 CAD 
Caffeine from coffee rs6063085 20 45840459 A C 0.625251 -0.01571 0.00237 0.011992 373522 4533.476 1.88E-10 3.40E-11 CAD 
Caffeine from coffee rs181251778 22 24901968 A G 0.986146 0.072648 0.009834 0.012039 373522 4551.664 1.53E-14 1.50E-13 CAD 
Caffeine from coffee rs4615895 1 96274668 G A 0.259574 -0.01705 0.002627 0.011992 373522 4533.705 1.92E-10 8.60E-11 T2D 
Caffeine from coffee rs7412396 1 150666797 G A 0.597371 -0.01297 0.002337 0.01197 373522 4525.166 1.35E-08 2.90E-08 T2D 
Caffeine from coffee rs7561317 2 644953 A G 0.171158 -0.02037 0.003043 0.01201 373522 4540.321 5.84E-12 2.20E-11 T2D 
Caffeine from coffee rs11127048 2 27752463 G A 0.381191 -0.01997 0.002398 0.012081 373522 4567.802 6.74E-18 8.10E-17 T2D 
Caffeine from coffee rs35198275 3 50536092 A G 0.865693 0.020797 0.003387 0.011987 373522 4531.599 4.48E-10 8.20E-10 T2D 
Caffeine from coffee rs2726513 4 106217358 G T 0.587077 0.015301 0.002347 0.011987 373522 4531.666 5.18E-10 7.00E-11 T2D 
Caffeine from coffee rs12514566 5 7391462 G A 0.664625 0.014831 0.002428 0.011991 373522 4533.052 2.31E-10 1.00E-09 T2D 
Caffeine from coffee rs6893807 5 87965021 A G 0.843563 -0.01916 0.003159 0.011983 373522 4530.283 9.38E-10 1.30E-09 T2D 
Caffeine from coffee rs1327259 6 51177811 A G 0.614152 0.015707 0.002365 0.011995 373522 4534.635 1.14E-10 3.10E-11 T2D 
Caffeine from coffee rs4410790 7 17284577 T C 0.364412 -0.05171 0.002384 0.013193 373522 4993.793 6.01E-110 2.80E-104 T2D 
Caffeine from coffee rs34060476 7 73037956 A G 0.865581 -0.02519 0.003365 0.012032 373522 4549.021 1.47E-13 7.10E-14 T2D 
Caffeine from coffee rs1057868 7 75615006 C T 0.714413 -0.02445 0.002536 0.012128 373522 4585.517 9.77E-22 5.50E-22 T2D 
Caffeine from coffee rs76881016 10 134196286 A G 0.928496 -0.02584 0.004453 0.011957 373522 4520.214 1.39E-07 6.60E-09 T2D 
Caffeine from coffee rs117810762 10 135315795 G A 0.982047 -0.05011 0.008765 0.011989 373522 4532.505 3.50E-10 1.10E-08 T2D 
Caffeine from coffee rs2298527 11 112851961 G C 0.405568 0.014947 0.002336 0.011978 373522 4528.319 2.77E-09 1.60E-10 T2D 
Caffeine from coffee rs2472297 15 75027880 C T 0.731859 -0.06521 0.002587 0.013586 373522 5144.517 1.83E-138 3.10E-140 T2D 
Caffeine from coffee rs2521501 15 91437388 A T 0.677316 0.014916 0.002472 0.011971 373522 4525.774 1.02E-08 1.60E-09 T2D 
Caffeine from coffee rs28567725 16 53826028 T C 0.5877 -0.02172 0.002331 0.012113 373522 4579.932 1.89E-20 1.20E-20 T2D 
Caffeine from coffee rs2350633 17 17587395 A G 0.486877 -0.01469 0.002296 0.012003 373522 4537.946 1.77E-11 1.60E-10 T2D 
Caffeine from coffee rs66723169 18 57808978 C A 0.769043 -0.02249 0.002732 0.012045 373522 4553.886 1.26E-14 1.80E-16 T2D 
Caffeine from coffee rs56113850 19 41353107 T C 0.421821 -0.02071 0.002323 0.012076 373522 4565.758 1.95E-17 4.90E-19 T2D 
Caffeine from coffee rs6063085 20 45840459 A C 0.625251 -0.01571 0.00237 0.011992 373522 4533.476 1.88E-10 3.40E-11 T2D 
Caffeine from coffee rs181251778 22 24901968 A G 0.986146 0.072648 0.009834 0.012039 373522 4551.664 1.53E-14 1.50E-13 T2D 
Caffeine from tea rs9438624 1 26758044 C T 0.19273 -0.01535 0.002844 0.011885 373522 4492.773 4.63E-01 6.70E-08 CAD 
Caffeine from tea rs11204708 1 150682095 C G 0.619872 -0.01428 0.002349 0.011959 373522 4521.126 1.04E-07 1.20E-09 CAD 
Caffeine from tea rs56188862 1 174189269 T C 0.614947 0.016829 0.002297 0.011884 373522 4492.339 7.38E-01 2.40E-13 CAD 
Caffeine from tea rs78020607 3 50254624 A G 0.887096 -0.01866 0.003527 0.011906 373522 4500.895 3.64E-03 1.20E-07 CAD 
Caffeine from tea rs2117137 3 89525505 A G 0.594554 -0.01349 0.002273 0.011896 373522 4497.011 2.98E-02 2.90E-09 CAD 
Caffeine from tea rs1481012 4 89039082 A G 0.887297 0.026005 0.003536 0.011945 373522 4515.799 1.13E-06 1.90E-13 CAD 
Caffeine from tea rs192084998 5 152077481 G A 0.703764 0.015836 0.002458 0.011885 373522 4492.581 5.55E-01 1.20E-10 CAD 
Caffeine from tea rs2465018 6 51241140 G A 0.769413 -0.02211 0.002666 0.011975 373522 4527.092 4.55E-09 1.10E-16 CAD 
Caffeine from tea rs139797380 6 137244957 C G 0.991607 0.075145 0.013059 0.011926 373522 4508.398 4.72E-05 8.70E-09 CAD 
Caffeine from tea rs4410790 7 17284577 T C 0.36537 -0.04033 0.00232 0.013193 373522 4993.793 6.01E-110 1.10E-67 CAD 
Caffeine from tea rs6462899 7 39296489 T A 0.375354 -0.01259 0.002312 0.011893 373522 4495.738 6.31E-02 5.10E-08 CAD 
Caffeine from tea rs17685 7 75616105 G A 0.721688 -0.02391 0.002488 0.012123 373522 4583.926 2.17E-21 7.20E-22 CAD 
Caffeine from tea rs62534435 9 7042938 C G 0.796528 -0.01629 0.002776 0.011885 373522 4492.788 4.57E-01 4.40E-09 CAD 
Caffeine from tea rs11022752 11 13307622 A G 0.730907 -0.01535 0.002525 0.011888 373522 4493.73 2.24E-01 1.20E-09 CAD 
Caffeine from tea rs10741694 11 16286183 T C 0.372823 -0.01474 0.002312 0.011885 373522 4492.73 4.82E-01 1.80E-10 CAD 
Caffeine from tea rs73053413 12 11329548 C T 0.836535 0.021681 0.003021 0.011946 373522 4516.148 1.15E-06 7.10E-13 CAD 
Caffeine from tea rs12591786 15 60902512 C T 0.842256 0.019576 0.003109 0.011894 373522 4495.968 5.41E-02 3.00E-10 CAD 








GWAS trait SNP CHR hg19 EFAL NEFAL EF Freq BETA SE R2 N F Statistic P STATA P GWAS MR 
Caffeine from tea rs28429148 16 53798319 G A 0.565413 0.013189 0.002288 0.012094 373522 4572.593 6.52E-19 8.20E-09 CAD 
Caffeine from tea rs153328 16 63025865 C G 0.782673 -0.01445 0.002718 0.011884 373522 4492.32 7.60E-01 1.10E-07 CAD 
Caffeine from tea rs140775622 20 62962869 C T 0.830545 -0.02262 0.003207 0.011916 373522 4504.501 5.30E-04 1.80E-12 CAD 
Caffeine from tea rs4817505 21 34343828 T C 0.607874 -0.01512 0.002292 0.01192 373522 4506.003 2.31E-04 4.20E-11 CAD 
Caffeine from tea rs9624470 22 24820268 G A 0.419254 -0.02534 0.002272 0.011889 373522 4494.15 1.69E-01 6.80E-29 CAD 
Caffeine from tea rs132919 22 41809903 G C 0.22639 -0.01708 0.002697 0.011893 373522 4495.762 6.25E-02 2.40E-10 CAD 
Caffeine from tea rs9438624 1 26758044 C T 0.19273 -0.01535 0.002844 0.011885 373522 4492.773 4.63E-01 6.70E-08 T2D 
Caffeine from tea rs11204710 1 150682110 A G 0.619798 -0.01427 0.002348 0.01196 373522 4521.319 9.45E-08 1.20E-09 T2D 
Caffeine from tea rs56188862 1 174189269 T C 0.614947 0.016829 0.002297 0.011884 373522 4492.339 7.38E-01 2.40E-13 T2D 
Caffeine from tea rs78020607 3 50254624 A G 0.887096 -0.01866 0.003527 0.011906 373522 4500.895 3.64E-03 1.20E-07 T2D 
Caffeine from tea rs2117137 3 89525505 A G 0.594554 -0.01349 0.002273 0.011896 373522 4497.011 2.98E-02 2.90E-09 T2D 
Caffeine from tea rs1481012 4 89039082 A G 0.887297 0.026005 0.003536 0.011945 373522 4515.799 1.13E-06 1.90E-13 T2D 
Caffeine from tea rs192084998 5 152077481 G A 0.703764 0.015836 0.002458 0.011885 373522 4492.581 5.55E-01 1.20E-10 T2D 
Caffeine from tea rs2465018 6 51241140 G A 0.769413 -0.02211 0.002666 0.011975 373522 4527.092 4.55E-09 1.10E-16 T2D 
Caffeine from tea rs139797380 6 137244957 C G 0.991607 0.075145 0.013059 0.011926 373522 4508.398 4.72E-05 8.70E-09 T2D 
Caffeine from tea rs4410790 7 17284577 T C 0.36537 -0.04033 0.00232 0.013193 373522 4993.793 6.01E-110 1.10E-67 T2D 
Caffeine from tea rs6462899 7 39296489 T A 0.375354 -0.01259 0.002312 0.011893 373522 4495.738 6.31E-02 5.10E-08 T2D 
Caffeine from tea rs17685 7 75616105 G A 0.721688 -0.02391 0.002488 0.012123 373522 4583.926 2.17E-21 7.20E-22 T2D 
Caffeine from tea rs62534435 9 7042938 C G 0.796528 -0.01629 0.002776 0.011885 373522 4492.788 4.57E-01 4.40E-09 T2D 
Caffeine from tea rs11022752 11 13307622 A G 0.730907 -0.01535 0.002525 0.011888 373522 4493.73 2.24E-01 1.20E-09 T2D 
Caffeine from tea rs10741694 11 16286183 T C 0.372823 -0.01474 0.002312 0.011885 373522 4492.73 4.82E-01 1.80E-10 T2D 
Caffeine from tea rs73053413 12 11329548 C T 0.836535 0.021681 0.003021 0.011946 373522 4516.148 1.15E-06 7.10E-13 T2D 
Caffeine from tea rs12591786 15 60902512 C T 0.842256 0.019576 0.003109 0.011894 373522 4495.968 5.41E-02 3.00E-10 T2D 
Caffeine from tea rs2472297 15 75027880 C T 0.732806 -0.05411 0.002521 0.013586 373522 5144.517 1.83E-138 3.30E-102 T2D 
Caffeine from tea rs28429148 16 53798319 G A 0.565413 0.013189 0.002288 0.012094 373522 4572.593 6.52E-19 8.20E-09 T2D 
Caffeine from tea rs153328 16 63025865 C G 0.782673 -0.01445 0.002718 0.011884 373522 4492.32 7.60E-01 1.10E-07 T2D 
Caffeine from tea rs140775622 20 62962869 C T 0.830545 -0.02262 0.003207 0.011916 373522 4504.501 5.30E-04 1.80E-12 T2D 
Caffeine from tea rs4817505 21 34343828 T C 0.607874 -0.01512 0.002292 0.01192 373522 4506.003 2.31E-04 4.20E-11 T2D 
Caffeine from tea rs9624470 22 24820268 G A 0.419254 -0.02534 0.002272 0.011889 373522 4494.15 1.69E-01 6.80E-29 T2D 
Caffeine from tea rs132919 22 41809903 G C 0.22639 -0.01708 0.002697 0.011893 373522 4495.762 6.25E-02 2.40E-10 T2D 
P values from the linear regression in STATA may differ from the GWAS P value since BOLT-LMM assumes a slightly different model. An F-statistic >10 indicates low risk of weak instrument bias in Mendelian randomization analyses. F-statistics were calculated as F=R2*(n-2)/(1-R2) where R2 is the proportion of 
variability in caffeine intake explained by the SNP. The outcome of the MR for which the SNPs are included is indicated by CAD or MR. Abbreviations: SNP, single nucleotide polymorphism; CHR, chromosome; EFAL, effect allele; NEFAL, non-effect allele; EF Freq, effect allele frequency; SE, standard error; CAD, 









Table S24. Heterogeneity (I2, Cochran's Q, Rücker's Q', and Q-Q'),  pleiotropy (MR-Egger intercept) and weak instrument statistics (I2GX) in Mendelian randomization analyses between caffeine intake and 























P value  
Rücker's Q' 













0.55735 0.77899 110 34 9.70E-10 110 33 5.40E-10 8.70E-02 1 0.77 -0.00091 0.00559 0.87 0.99 
Caffeine from coffee CAD 0.8085
6 
0.71856 0.86978 110 21 5.40E-14 110 20 8.90E-14 3.3 1 0.069 -0.00900 0.01140 0.44 0.99 
Caffeine from tea CAD 0.6063
8 





0.59298 0.79391 120 34 4.20E-11 110 33 1.50E-10 5.3 1 0.021 0.00911 0.00726 0.22 0.99 
Caffeine from coffee T2D 0.8459
9 
0.78048 0.89195 140 22 1.10E-19 130 21 1.30E-18 8.1 1 0.004 0.01744 0.01550 0.27 0.99 
Caffeine from tea T2D 0.7976
0 
0.70575 0.86078 110 23 5.70E-14 100 22 8.70E-13 8.7 1 0.003 -0.02059 0.01527 0.19 0.98 









Table S25. Excluded variants in MR-PRESSO analyses on CAD and T2D 
Combined caffeine intake SNPs Caffeine from coffee SNPs Caffeine from tea SNPs 
Outlier SNP RSSobs P value Outcome Outlier SNP RSSobs P 
value 
Outcome Outlier SNP RSSobs P 
value 
Outcome 
rs1490384 0.001195111 0.05 CAD rs2350633 0.001956 <0.05 CAD rs11022752 0.002 <0.05 CAD 
rs4418728 0.001363837 <0.05 CAD rs2521501 0.00415 <0.05 CAD rs4410790 0.0014 <0.05 CAD 
rs489693 0.002065843 <0.05 CAD rs66723169 0.003039 <0.05 CAD rs28429148 0.0151 <0.05 T2D 
rs595529 0.002935062 <0.05 CAD rs7412396 0.000736 0.05 CAD 
    
rs1490384 0.003607685 <0.05 T2D rs2350633 0.00191 <0.05 T2D 
    
rs2667773 0.001851194 <0.05 T2D rs28567725 0.012255 <0.05 T2D 
    
rs489693 0.002973746 <0.05 T2D rs66723169 0.002487 <0.05 T2D     
Mendelian Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) outlier information for the excluded variants per outcome. Abbreviations: CAD, coronary artery disease; T2D, type 2 diabetes; SNP, 









Table S26. Mendelian randomization analyses results after MR-Steiger filtering 
MR Method n SNPs Beta SE P value Outcome Filtered SNPs Exposure 
Inverse variance weighted (fixed 







MR Egger 32 0.18 0.13 0.182 
Weighted median 32 0.05 0.11 0.653 
Inverse variance weighted 
(multiplicative random effects) 32 0.09 0.08 0.274 
Weighted mode 32 0.14 0.09 0.121 
Inverse variance weighted (fixed 







MR Egger 19 0.27 0.28 0.35 
Weighted median 19 0.29 0.15 0.05 
Inverse variance weighted 
(multiplicative random effects) 19 0.27 0.14 0.05 
Weighted mode 19 0.06 0.18 0.76 
Inverse variance weighted (fixed 




MR Egger 23 0.37 0.34 0.30 
Weighted median 23 -0.05 0.19 0.78 
Inverse variance weighted 
(multiplicative random effects) 23 0.01 0.15 0.93 
Weighted mode 23 0.03 0.25 0.92 
Inverse variance weighted (fixed 




MR Egger 34 0.12 0.21 0.59 
Weighted median 34 0.14 0.11 0.21 
Inverse variance weighted 
(multiplicative random effects) 34 0.25 0.13 0.07 
Weighted mode 34 0.16 0.11 0.13 
Inverse variance weighted (fixed 
effects) 22 0.43 0.12 4.51E-04 T2D rs28567725 
Caffeine from 
coffee 








MR Method n SNPs Beta SE P value Outcome Filtered SNPs Exposure 
Weighted median 22 0.24 0.17 0.17    
Inverse variance weighted 
(multiplicative random effects) 22 0.43 0.21 0.04 
Weighted mode 22 0.24 0.16 0.15 
Inverse variance weighted (fixed 




MR Egger 23 0.37 0.35 0.30 
Weighted median 23 0.27 0.20 0.18 
Inverse variance weighted 
(multiplicative random effects) 23 0.22 0.15 0.15 
Weighted mode 23 0.23 0.21 0.29 
Mendelian randomization (MR) analysis method results for the association between genetically determined higher caffeine intake on coronary artery disease or type 2 diabetes after filtering of SNPs more strongly 









Table S27. SNPs and proxies for Mendelian Randomization analyses for combined caffeine intake on type 2 diabetes 
SNP CHR BP ALLELE1 ALLELE0 A1FREQ BETA SE P value Proxy for R2 
rs7412396 1 150666797 G A 0.597491 -0.02279 0.002364 5.50E-22 rs768283768 0.930744 
rs2987869 1 174789407 G T 0.458638 -0.01562 0.002332 2.10E-11 1:174856749_TG_T 0.998626 
rs1260326 2 27730940 T C 0.391852 -0.02297 0.002377 4.20E-22 
  
rs78456557 3 123300686 C G 0.900201 -0.02364 0.00389 1.20E-09 
  
rs114066728 3 142022265 T C 0.870043 -0.02127 0.003456 7.50E-10 rs115454798 0.991139 
rs2231142 4 89052323 G T 0.886707 0.03913 0.00366 1.10E-26 
  
rs62332762 4 106143492 C T 0.597585 0.01828 0.002368 1.20E-14 
  
rs12514566 5 7391462 G A 0.664698 0.017242 0.002456 2.20E-12 
  
rs1872841 6 98576688 C A 0.483724 -0.01316 0.002328 1.60E-08 rs754177720 0.902704 
rs9486902 6 108878052 C T 0.837869 0.018849 0.00315 2.20E-09 6:108876096_CAAT_C 0.997488 
rs1490384 6 126851160 C T 0.501467 -0.01587 0.002323 8.30E-12 
  
rs139797380 6 137244957 C G 0.991601 0.106741 0.013575 3.70E-15 
  
rs4410790 7 17284577 T C 0.364122 -0.08137 0.002412 1.50E-249 
  
rs215601 7 32333921 A C 0.372618 0.01488 0.002404 6.00E-10 
  
rs34060476 7 73037956 A G 0.865587 -0.03535 0.003404 2.90E-25 7:73042302_GCTTT_G 0.99198 
rs17685 7 75616105 G A 0.721471 -0.0408 0.002584 3.80E-56 
  
rs4240624 8 9184231 G A 0.092461 0.02693 0.004012 1.90E-11 
  
rs12785227 10 65262685 A G 0.685798 0.014549 0.002507 6.50E-09 
  
rs4418728 10 94839724 G T 0.550788 0.014384 0.002333 7.00E-10 
  
rs117810762 10 135315795 G A 0.982023 -0.06827 0.008863 1.30E-14 
  
rs6265 11 27679916 C T 0.810755 0.021572 0.002964 3.40E-13 
  
rs1228024 11 47951353 C A 0.340021 0.013965 0.002453 1.30E-08 
  
rs7105462 11 112912048 G A 0.40559 0.014163 0.002366 2.10E-09 
  
rs607316 12 111969448 C T 0.795666 -0.01678 0.002878 5.50E-09 rs376877108 0.993627 
rs12591786 15 60902512 C T 0.842038 0.020213 0.00323 3.90E-10 
  
rs2472297 15 75027880 C T 0.731645 -0.10487 0.002616 2.4E-351 
  









SNP CHR BP ALLELE1 ALLELE0 A1FREQ BETA SE P value Proxy for R2 
rs3965574 16 18789966 A G 0.61805 0.013716 0.002416 1.40E-08 16:18776851_G_GA 0.934833 
rs489693 18 57882787 C A 0.67465 -0.01759 0.002478 1.30E-12 
  
rs56113850 19 41353107 T C 0.421755 -0.02649 0.002351 1.90E-29 
  
rs61599759 19 47557472 A G 0.245811 -0.01741 0.002732 1.80E-10 rs61141867 0.984394 
rs1291145 20 35528475 T C 0.313259 -0.01456 0.002506 6.30E-09 20:35568001_AAAAG_A 0.998402 
rs6062679 20 62889991 T C 0.534615 -0.02278 0.002358 4.50E-22 
  
rs138019862 22 24821154 G T 0.986106 0.093407 0.009925 4.90E-21 rs199612805 1 
rs9611527 22 41644428 G A 0.664286 0.019792 0.002466 1.00E-15 
  
Sentinel single nucleotide polymorphisms (SNPs) and proxies used are provided for the Mendelian randomization analyses. In case a proxy was used, the original sentinel SNP is provided in the "Proxy for" column and 









Table S28. SNPs and proxies for Mendelian Randomization analyses for caffeine from coffee on type 2 diabetes 
SNP CHR BP ALLELE1 ALLELE0 A1FREQ BETA SE P value Proxy for R2 
rs4615895 1 96274668 G A 0.259574 -0.01705 0.002627 8.60E-11 
  
rs7412396 1 150666797 G A 0.597371 -0.01297 0.002337 2.90E-08 rs768283768 0.930744 
rs7561317 2 644953 A G 0.171158 -0.02037 0.003043 2.20E-11 rs7571970 0.99315 
rs11127048 2 27752463 G A 0.381191 -0.01997 0.002398 8.10E-17 
  
rs35198275 3 50536092 A G 0.865693 0.020797 0.003387 8.20E-10 
  
rs2726513 4 106217358 G T 0.587077 0.015301 0.002347 7.00E-11 
  
rs12514566 5 7391462 G A 0.664625 0.014831 0.002428 1.00E-09 
  
rs6893807 5 87965021 A G 0.843563 -0.01916 0.003159 1.30E-09 
  
rs1327259 6 51177811 A G 0.614152 0.015707 0.002365 3.10E-11 
  
rs4410790 7 17284577 T C 0.364412 -0.05171 0.002384 2.80E-104 
  
rs34060476 7 73037956 A G 0.865581 -0.02519 0.003365 7.10E-14 
  
rs1057868 7 75615006 C T 0.714413 -0.02445 0.002536 5.50E-22 
  
rs76881016 10 134196286 A G 0.928496 -0.02584 0.004453 6.60E-09 
  
rs117810762 10 135315795 G A 0.982047 -0.05011 0.008765 1.10E-08 
  
rs2298527 11 112851961 G C 0.405568 0.014947 0.002336 1.60E-10 
  
rs2472297 15 75027880 C T 0.731859 -0.06521 0.002587 3.10E-140 
  
rs2521501 15 91437388 A T 0.677316 0.014916 0.002472 1.60E-09 
  
rs28567725 16 53826028 T C 0.5877 -0.02172 0.002331 1.20E-20 rs201399553 0.945928 
rs2350633 17 17587395 A G 0.486877 -0.01469 0.002296 1.60E-10 rs139937261 0.997277 
rs66723169 18 57808978 C A 0.769043 -0.02249 0.002732 1.80E-16 
  
rs56113850 19 41353107 T C 0.421821 -0.02071 0.002323 4.90E-19 
  
rs6063085 20 45840459 A C 0.625251 -0.01571 0.00237 3.40E-11 
  
rs181251778 22 24901968 A G 0.986146 0.072648 0.009834 1.50E-13 
  
Sentinel single nucleotide polymorphisms (SNPs) and proxies used are provided for the Mendelian randomization analyses. In case a proxy was used, the original sentinel SNP is provided in the "Proxy for" column and 









Table S29. SNPs and proxies for Mendelian Randomization analyses for caffeine from tea on type 2 diabetes 
SNP CHR BP ALLELE1 ALLELE0 A1FREQ BETA SE P value Proxy for R2 
rs9438624 1 26758044 C T 0.19273 -0.01535 0.002844 6.70E-08 rs77476394 0.887444 
rs11204710 1 150682110 A G 0.619798 -0.01427 0.002348 1.20E-09 rs11204711 0.998421 
rs56188862 1 174189269 T C 0.614947 0.016829 0.002297 2.40E-13 
  
rs78020607 3 50254624 A G 0.887096 -0.01866 0.003527 1.20E-07 rs145755097 0.869438 
rs2117137 3 89525505 A G 0.594554 -0.01349 0.002273 2.90E-09 
  
rs1481012 4 89039082 A G 0.887297 0.026005 0.003536 1.90E-13 
  
rs192084998 5 152077481 G A 0.703764 0.015836 0.002458 1.20E-10 
  
rs2465018 6 51241140 G A 0.769413 -0.02211 0.002666 1.10E-16 
  
rs139797380 6 137244957 C G 0.991607 0.075145 0.013059 8.70E-09 
  
rs4410790 7 17284577 T C 0.36537 -0.04033 0.00232 1.10E-67 
  
rs6462899 7 39296489 T A 0.375354 -0.01259 0.002312 5.10E-08 rs141180025 0.943469 
rs17685 7 75616105 G A 0.721688 -0.02391 0.002488 7.20E-22 
  
rs62534435 9 7042938 C G 0.796528 -0.01629 0.002776 4.40E-09 
  
rs11022752 11 13307622 A G 0.730907 -0.01535 0.002525 1.20E-09 
  
rs10741694 11 16286183 T C 0.372823 -0.01474 0.002312 1.80E-10 
  
rs73053413 12 11329548 C T 0.836535 0.021681 0.003021 7.10E-13 
  
rs12591786 15 60902512 C T 0.842256 0.019576 0.003109 3.00E-10 
  
rs2472297 15 75027880 C T 0.732806 -0.05411 0.002521 3.30E-102 
  
rs28429148 16 53798319 G A 0.565413 0.013189 0.002288 8.20E-09 
  
rs153328 16 63025865 C G 0.782673 -0.01445 0.002718 1.10E-07 rs199602679 0.976937 
rs140775622 20 62962869 C T 0.830545 -0.02262 0.003207 1.80E-12 
  
rs4817505 21 34343828 T C 0.607874 -0.01512 0.002292 4.20E-11 
  
rs9624470 22 24820268 G A 0.419254 -0.02534 0.002272 6.80E-29 
  
rs132919 22 41809903 G C 0.22639 -0.01708 0.002697 2.40E-10 
  
Sentinel single nucleotide polymorphisms (SNPs) and proxies used are provided for the Mendelian randomization analyses. In case a proxy was used, the original sentinel SNP is provided in the "Proxy for" column and 








Figure S1. UK Biobank study population selection 
 
Study sample selection flowchart. Section A depicts the selection procedure leading up to the total number of participants included in one or 
more genome wide association study (B) and the number of new-onset cases and controls within each genetic cohort that were included in 









Figure S2. Manhattan plot for caffeine from coffee 
 
Manhattan plot showing the results for the genome-wide associations with caffeine from coffee in the UK Biobank with the –log10 P value on the vertical axis. The sentinel single nucleotide polymorphisms that 









Figure S3. Manhattan plot for caffeine from tea 
  
Manhattan plot showing the results for the genome-wide associations with caffeine from tea in the UK Biobank with the –log10 P value on the vertical axis. The sentinel single nucleotide polymorphisms that reached 









Figure S4. Overlay Manhattan plot based on lowest P value for all caffeine intake traits 
 
Overlay Manhattan plot showing the results for the genome-wide associations with caffeine intake over all traits based on the lowest P value within the UK Biobank with the –log10 P value on the vertical axis. The 
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